|
G |
Chit1 |
chitinase 1 |
affects binding |
ISO |
CHIT1 protein binds to Chitin |
CTD |
PMID:16005164 |
|
NCBI chr13:50,947,020...50,994,644
Ensembl chr13:50,974,872...50,994,643
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
multiple interactions |
ISO |
[Protein Synthesis Inhibitors binds to Chitin] which results in decreased expression of IGF1R mRNA |
CTD |
PMID:30041514 |
|
NCBI chr 1:128,924,921...129,213,816
Ensembl chr 1:128,924,966...129,206,516
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
[[Aptamers, Nucleotide binds to Chitin] which binds to MUC1 protein] promotes the reaction [[Docetaxel binds to Chitin] which results in decreased expression of MMP9 mRNA]; [[Aptamers, Nucleotide binds to Chitin] which binds to MUC1 protein] promotes the reaction [[Protein Synthesis Inhibitors binds to Chitin] which results in decreased expression of MMP9 mRNA]; [Docetaxel binds to Chitin] which results in decreased expression of MMP9 mRNA; [Protein Synthesis Inhibitors binds to Chitin] which results in decreased expression of MMP9 mRNA |
CTD |
PMID:30041514 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Muc1 |
mucin 1, cell surface associated |
affects binding multiple interactions |
ISO |
[Aptamers, Nucleotide binds to Chitin] which binds to MUC1 protein [[Aptamers, Nucleotide binds to Chitin] which binds to MUC1 protein] promotes the reaction [[Docetaxel binds to Chitin] which results in decreased expression of MMP9 mRNA]; [[Aptamers, Nucleotide binds to Chitin] which binds to MUC1 protein] promotes the reaction [[Docetaxel binds to Chitin] which results in decreased expression of VEGFA mRNA]; [[Aptamers, Nucleotide binds to Chitin] which binds to MUC1 protein] promotes the reaction [[Protein Synthesis Inhibitors binds to Chitin] which results in decreased expression of MMP9 mRNA]; [[Aptamers, Nucleotide binds to Chitin] which binds to MUC1 protein] promotes the reaction [[Protein Synthesis Inhibitors binds to Chitin] which results in decreased expression of STAT3 mRNA]; [[Aptamers, Nucleotide binds to Chitin] which binds to MUC1 protein] promotes the reaction [[Protein Synthesis Inhibitors binds to Chitin] which results in decreased expression of VEGFA mRNA]; [[Aptamers, Nucleotide binds to Chitin] which binds to MUC1 protein] which results in increased uptake of Docetaxel; [[Aptamers, Nucleotide binds to Chitin] which binds to MUC1 protein] which results in increased uptake of Protein Synthesis Inhibitors |
CTD |
PMID:30041514 |
|
NCBI chr 2:188,543,137...188,547,874
Ensembl chr 2:188,543,137...188,547,874
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
[[Aptamers, Nucleotide binds to Chitin] which binds to MUC1 protein] promotes the reaction [[Protein Synthesis Inhibitors binds to Chitin] which results in decreased expression of STAT3 mRNA]; [Docetaxel binds to Chitin] which results in decreased expression of STAT3 mRNA; [Protein Synthesis Inhibitors binds to Chitin] which results in decreased expression of STAT3 mRNA |
CTD |
PMID:30041514 |
|
NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
[[Aptamers, Nucleotide binds to Chitin] which binds to MUC1 protein] promotes the reaction [[Docetaxel binds to Chitin] which results in decreased expression of VEGFA mRNA]; [[Aptamers, Nucleotide binds to Chitin] which binds to MUC1 protein] promotes the reaction [[Protein Synthesis Inhibitors binds to Chitin] which results in decreased expression of VEGFA mRNA]; [Docetaxel binds to Chitin] which results in decreased expression of VEGFA mRNA; [Protein Synthesis Inhibitors binds to Chitin] which results in decreased expression of VEGFA mRNA |
CTD |
PMID:30041514 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
EXP |
[Chitosan co-treated with Fish Oils] inhibits the reaction [Dietary Fats results in decreased expression of ABCA1 mRNA]; Chitosan inhibits the reaction [Dietary Fats results in decreased expression of ABCA1 mRNA] |
CTD |
PMID:28987369 |
|
NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
[Cromolyn Sodium co-treated with Chitosan] inhibits the reaction [Dimethylhydrazines results in increased expression of AKT1 protein] |
CTD |
PMID:28732690 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Alad |
aminolevulinate dehydratase |
multiple interactions |
EXP |
[Curcumin co-treated with Chitosan analog] inhibits the reaction [Arsenic results in decreased activity of ALAD protein] |
CTD |
PMID:22704994 |
|
NCBI chr 5:78,368,867...78,379,206
Ensembl chr 5:78,368,867...78,379,346
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
increases expression |
ISO |
Chitosan results in increased expression of ALPL mRNA; Chitosan results in increased expression of ALPL protein |
CTD |
PMID:25246786 |
|
NCBI chr 5:156,086,496...156,141,513
Ensembl chr 5:156,086,497...156,141,537
|
|
G |
Aox1 |
aldehyde oxidase 1 |
multiple interactions |
EXP |
[Chitosan co-treated with Fish Oils] inhibits the reaction [Dietary Fats results in decreased expression of AOX1 mRNA]; Chitosan inhibits the reaction [Dietary Fats results in decreased expression of AOX1 mRNA] |
CTD |
PMID:28987369 |
|
NCBI chr 9:64,929,682...65,007,872
Ensembl chr 9:64,929,721...65,007,870
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO EXP |
[Fluorouracil co-treated with Chitosan co-treated with polyaspartate] results in increased expression of BAX protein Chitosan analog inhibits the reaction [Doxorubicin results in increased expression of BAX protein] |
CTD |
PMID:18567086 PMID:30928397 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO EXP |
[Fluorouracil co-treated with Chitosan co-treated with polyaspartate] results in decreased expression of BCL2 protein [Cromolyn Sodium co-treated with Chitosan] inhibits the reaction [Dimethylhydrazines results in increased expression of BCL2 protein]; Chitosan analog inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] |
CTD |
PMID:18567086 PMID:28732690 PMID:30928397 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression |
ISO |
Chitosan results in increased expression of BGLAP mRNA |
CTD |
PMID:25246786 |
|
NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
Chitosan metabolite inhibits the reaction [Copper results in increased activity of CASP3 protein] Chitosan analog inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein] |
CTD |
PMID:25542178 PMID:30928397 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
Chitosan analog inhibits the reaction [Doxorubicin results in increased expression of CASP9 protein] |
CTD |
PMID:30928397 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
[Chitosan analog co-treated with Quercetin] inhibits the reaction [ochratoxin A results in decreased activity of CAT protein]; [Curcumin co-treated with Chitosan analog] inhibits the reaction [Arsenic results in decreased activity of CAT protein]; Chitosan analog inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]; Chitosan analog inhibits the reaction [ochratoxin A results in decreased activity of CAT protein]; Chitosan inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein] |
CTD |
PMID:12679053 PMID:22704994 PMID:27923682 PMID:30928397 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Clec7a |
C-type lectin domain containing 7A |
multiple interactions decreases expression |
ISO |
Chitosan inhibits the reaction [Lipopolysaccharides results in decreased expression of CLEC7A mRNA] Chitosan results in decreased expression of CLEC7A mRNA |
CTD |
PMID:21329777 |
|
NCBI chr 4:163,216,152...163,227,367
Ensembl chr 4:163,216,163...163,227,334
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
EXP |
[Cromolyn Sodium co-treated with Chitosan] inhibits the reaction [Dimethylhydrazines results in increased expression of CTNNB1 protein] |
CTD |
PMID:28732690 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
increases activity |
ISO |
Chitosan analog results in increased activity of CYP3A4 protein |
CTD |
PMID:20831879 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions |
EXP |
Chitosan inhibits the reaction [Dietary Fats results in increased expression of CYP7A1 mRNA]; Fish Oils promotes the reaction [Chitosan inhibits the reaction [Dietary Fats results in increased expression of CYP7A1 mRNA]] |
CTD |
PMID:28987369 |
|
NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions |
EXP |
[Fish Oils co-treated with Chitosan] inhibits the reaction [Dietary Fats results in increased expression of FABP4 mRNA]; Chitosan inhibits the reaction [Dietary Fats results in increased expression of FABP4 mRNA] |
CTD |
PMID:28987369 |
|
NCBI chr 2:93,792,666...93,797,267
Ensembl chr 2:93,792,601...93,797,305
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
EXP |
[Fish Oils co-treated with Chitosan] inhibits the reaction [Dietary Fats results in increased expression of FASN mRNA]; Chitosan inhibits the reaction [Dietary Fats results in increased expression of FASN mRNA] |
CTD |
PMID:28987369 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Gcg |
glucagon |
increases expression increases secretion multiple interactions |
ISO |
Chitosan results in increased expression of GCG mRNA Chitosan results in increased secretion of GCG protein SB 203580 inhibits the reaction [Chitosan results in increased expression of GCG mRNA]; SB 203580 inhibits the reaction [Chitosan results in increased secretion of GCG protein] |
CTD |
PMID:23611362 |
|
NCBI chr 3:48,442,635...48,451,650
Ensembl chr 3:48,442,635...48,451,650
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases expression multiple interactions |
EXP |
Chitosan analog results in increased expression of GPX1 mRNA [Chitosan analog co-treated with Quercetin] inhibits the reaction [ochratoxin A results in decreased expression of GPX1 mRNA]; [Chitosan analog co-treated with Quercetin] results in increased expression of GPX1 mRNA; Chitosan analog inhibits the reaction [ochratoxin A results in decreased expression of GPX1 mRNA] |
CTD |
PMID:27923682 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP |
[Cromolyn Sodium co-treated with Chitosan] inhibits the reaction [Dimethylhydrazines results in increased expression of GSK3B protein] |
CTD |
PMID:28732690 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
Chitosan analog inhibits the reaction [Doxorubicin results in decreased expression of GSR mRNA] |
CTD |
PMID:30928397 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
EXP |
[Fish Oils co-treated with Chitosan] inhibits the reaction [Dietary Fats results in increased expression of HMGCR mRNA]; Chitosan inhibits the reaction [Dietary Fats results in increased expression of HMGCR mRNA] |
CTD |
PMID:28987369 |
|
NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO EXP |
[Chitosan metabolite results in decreased susceptibility to Copper] which results in increased expression of HMOX1 mRNA; [Chitosan metabolite results in decreased susceptibility to Copper] which results in increased expression of HMOX1 protein Chitosan analog inhibits the reaction [Doxorubicin results in decreased expression of HMOX1 mRNA] |
CTD |
PMID:25542178 PMID:30928397 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases secretion |
ISO |
Chitosan inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] Chitosan results in increased secretion of IL10 protein |
CTD |
PMID:21329777 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il6 |
interleukin 6 |
increases secretion multiple interactions |
ISO |
Chitosan results in increased secretion of IL6 protein Chitosan inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:21329777 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
[Cromolyn Sodium co-treated with Chitosan] inhibits the reaction [Dimethylhydrazines results in increased expression of MAPK3 protein] |
CTD |
PMID:28732690 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
EXP |
Chitosan inhibits the reaction [Aminolevulinic Acid analog results in increased activity of MMP2 protein] |
CTD |
PMID:18806744 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions affects localization |
ISO EXP |
[Chitosan metabolite results in decreased susceptibility to Copper] which results in increased phosphorylation of NFE2L2 protein Chitosan analog inhibits the reaction [Doxorubicin affects the localization of NFE2L2 protein]; pyrazolanthrone inhibits the reaction [Chitosan analog inhibits the reaction [Doxorubicin affects the localization of NFE2L2 protein]]; SB 203580 inhibits the reaction [Chitosan analog inhibits the reaction [Doxorubicin affects the localization of NFE2L2 protein]] Chitosan analog affects the localization of NFE2L2 protein |
CTD |
PMID:25542178 PMID:30928397 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
Chitosan analog inhibits the reaction [Doxorubicin results in decreased expression of NQO1 mRNA] |
CTD |
PMID:30928397 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
EXP |
[Chitosan co-treated with Fish Oils] inhibits the reaction [Dietary Fats results in increased expression of NR1H3 protein] |
CTD |
PMID:28987369 |
|
NCBI chr 3:80,004,130...80,014,197
Ensembl chr 3:80,004,130...80,012,750
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
[Chitosan co-treated with Fish Oils] inhibits the reaction [Dietary Fats results in decreased expression of PPARA protein] |
CTD |
PMID:28987369 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
[Cromolyn Sodium co-treated with Chitosan] inhibits the reaction [Dimethylhydrazines results in increased expression of RELA protein] |
CTD |
PMID:28732690 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
increases expression |
ISO |
Chitosan results in increased expression of RUNX2 mRNA; Chitosan results in increased expression of RUNX2 protein |
CTD |
PMID:25246786 |
|
NCBI chr 9:18,564,743...18,773,092
Ensembl chr 9:18,564,927...18,773,092
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions increases expression |
EXP |
[Chitosan analog co-treated with Quercetin] results in increased expression of SOD1 mRNA; Chitosan analog inhibits the reaction [Doxorubicin results in decreased expression of SOD1 mRNA] Chitosan analog results in increased expression of SOD1 mRNA |
CTD |
PMID:27923682 PMID:30928397 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression |
ISO |
Chitosan results in increased expression of SPP1 mRNA |
CTD |
PMID:25246786 |
|
NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
EXP |
[Fish Oils co-treated with Chitosan] inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA]; Chitosan inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA] |
CTD |
PMID:28987369 |
|
NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
EXP |
[Curcumin co-treated with Chitosan analog] inhibits the reaction [Arsenic results in decreased expression of TH protein] |
CTD |
PMID:22704994 |
|
NCBI chr 1:216,073,034...216,080,287
Ensembl chr 1:216,073,031...216,080,287
|
|
G |
Tlr2 |
toll-like receptor 2 |
multiple interactions decreases expression |
ISO |
Chitosan inhibits the reaction [Lipopolysaccharides results in decreased expression of TLR2 mRNA] Chitosan results in decreased expression of TLR2 mRNA |
CTD |
PMID:21329777 |
|
NCBI chr 2:182,840,171...182,846,061
Ensembl chr 2:182,840,727...182,846,061
|
|
G |
Tlr4 |
toll-like receptor 4 |
decreases expression multiple interactions |
ISO |
Chitosan results in decreased expression of TLR4 mRNA Chitosan inhibits the reaction [Lipopolysaccharides results in decreased expression of TLR4 mRNA] |
CTD |
PMID:21329777 |
|
NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion |
ISO |
Chitosan inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] Chitosan results in increased secretion of TNF protein |
CTD |
PMID:21329777 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tph1 |
tryptophan hydroxylase 1 |
multiple interactions |
EXP |
[Curcumin co-treated with Chitosan analog] inhibits the reaction [Arsenic results in decreased expression of TPH1 protein] |
CTD |
PMID:22704994 |
|
NCBI chr 1:102,669,868...102,699,442
Ensembl chr 1:102,669,868...102,699,442
|
|
|
G |
Arsb |
arylsulfatase B |
decreases abundance |
ISO |
ARSB protein results in decreased abundance of Chondroitin Sulfates |
CTD |
PMID:29794138 |
|
NCBI chr 2:23,385,154...23,543,028
Ensembl chr 2:23,385,183...23,544,963
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
multiple interactions |
EXP |
[icatibant binds to and results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to Chondroitin Sulfates |
CTD |
PMID:21436127 |
|
NCBI chr 6:129,399,468...129,429,676
Ensembl chr 6:129,399,468...129,429,676
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to BDNF protein |
CTD |
PMID:15385557 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
C3 |
complement C3 |
increases cleavage |
ISO |
Chondroitin Sulfates analog results in increased cleavage of C3 protein |
CTD |
PMID:18434646 |
|
NCBI chr 9:9,721,137...9,747,084
Ensembl chr 9:9,721,105...9,747,167
|
|
G |
C5 |
complement C5 |
increases cleavage |
ISO |
Chondroitin Sulfates analog results in increased cleavage of C5 protein |
CTD |
PMID:18434646 |
|
NCBI chr 3:14,049,993...14,113,931 NCBI chr 3:14,206,466...14,229,141
Ensembl chr 3:14,049,995...14,229,080
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP3 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP3 mRNA] |
CTD |
PMID:17879260 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
[Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP7 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP7 mRNA] |
CTD |
PMID:17879260 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Chondroitin Sulfates inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein] |
CTD |
PMID:12736501 PMID:15089041 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
affects binding |
ISO |
Chondroitin Sulfates binds to CCL2 protein |
CTD |
PMID:16385517 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
ISO |
Chondroitin Sulfates inhibits the reaction [CTSB protein results in increased degradation of CXCL10 protein]; Chondroitin Sulfates inhibits the reaction [CTSB protein results in increased degradation of CXCL11 protein]; Chondroitin Sulfates inhibits the reaction [CTSB protein results in increased degradation of CXCL9 protein]; Chondroitin Sulfates promotes the reaction [CTSB protein results in increased cleavage of benzyloxycarbonyl-phenylalanylarginine-4-methylcoumaryl-7-amide] |
CTD |
PMID:25833952 |
|
NCBI chr15:46,316,741...46,337,613
Ensembl chr15:46,316,741...46,337,612
|
|
G |
Ctsk |
cathepsin K |
multiple interactions |
ISO |
Chondroitin Sulfates inhibits the reaction [CTSK protein results in increased degradation of CXCL10 protein]; Chondroitin Sulfates promotes the reaction [CTSK protein results in increased cleavage of benzyloxycarbonyl-phenylalanylarginine-4-methylcoumaryl-7-amide]; Chondroitin Sulfates promotes the reaction [CTSK protein results in increased cleavage of CXCL1 protein]; Chondroitin Sulfates promotes the reaction [CTSK protein results in increased cleavage of CXCL2 protein]; Chondroitin Sulfates promotes the reaction [CTSK protein results in increased cleavage of CXCL3 protein] |
CTD |
PMID:25833952 |
|
NCBI chr 2:196,655,469...196,666,447
Ensembl chr 2:196,655,469...196,666,446
|
|
G |
Ctsl |
cathepsin L |
multiple interactions |
ISO |
Chondroitin Sulfates inhibits the reaction [CTSL protein results in increased degradation of CXCL10 protein]; Chondroitin Sulfates inhibits the reaction [CTSL protein results in increased degradation of CXCL11 protein]; Chondroitin Sulfates promotes the reaction [CTSL protein results in increased cleavage of benzyloxycarbonyl-phenylalanylarginine-4-methylcoumaryl-7-amide]; Chondroitin Sulfates promotes the reaction [CTSL protein results in increased cleavage of CXCL1 protein]; Chondroitin Sulfates promotes the reaction [CTSL protein results in increased cleavage of CXCL2 protein] |
CTD |
PMID:25833952 |
|
NCBI chr17:1,873,105...1,879,266
Ensembl chr17:1,872,848...1,879,279
|
|
G |
Ctss |
cathepsin S |
multiple interactions |
ISO |
Chondroitin Sulfates inhibits the reaction [CTSS protein results in increased degradation of CXCL10 protein]; Chondroitin Sulfates promotes the reaction [CTSS protein results in increased cleavage of benzyloxycarbonyl-phenylalanylarginine-4-methylcoumaryl-7-amide]; Chondroitin Sulfates promotes the reaction [CTSS protein results in increased cleavage of CXCL1 protein]; Chondroitin Sulfates promotes the reaction [CTSS protein results in increased cleavage of CXCL2 protein] |
CTD |
PMID:25833952 |
|
NCBI chr 2:197,655,780...197,679,768
Ensembl chr 2:197,655,786...197,679,458
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions |
ISO |
Chondroitin Sulfates promotes the reaction [CTSK protein results in increased cleavage of CXCL1 protein]; Chondroitin Sulfates promotes the reaction [CTSL protein results in increased cleavage of CXCL1 protein]; Chondroitin Sulfates promotes the reaction [CTSS protein results in increased cleavage of CXCL1 protein] |
CTD |
PMID:25833952 |
|
NCBI chr14:18,743,678...18,745,457
Ensembl chr14:18,743,685...18,745,457
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
Chondroitin Sulfates inhibits the reaction [CTSB protein results in increased degradation of CXCL10 protein]; Chondroitin Sulfates inhibits the reaction [CTSK protein results in increased degradation of CXCL10 protein]; Chondroitin Sulfates inhibits the reaction [CTSL protein results in increased degradation of CXCL10 protein]; Chondroitin Sulfates inhibits the reaction [CTSS protein results in increased degradation of CXCL10 protein] |
CTD |
PMID:25833952 |
|
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
multiple interactions |
ISO |
Chondroitin Sulfates inhibits the reaction [CTSB protein results in increased degradation of CXCL11 protein]; Chondroitin Sulfates inhibits the reaction [CTSL protein results in increased degradation of CXCL11 protein] |
CTD |
PMID:25833952 |
|
NCBI chr14:17,195,395...17,198,170
Ensembl chr14:17,195,014...17,198,291
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Chondroitin Sulfates promotes the reaction [CTSK protein results in increased cleavage of CXCL2 protein]; Chondroitin Sulfates promotes the reaction [CTSL protein results in increased cleavage of CXCL2 protein]; Chondroitin Sulfates promotes the reaction [CTSS protein results in increased cleavage of CXCL2 protein] |
CTD |
PMID:25833952 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Chondroitin Sulfates promotes the reaction [CTSK protein results in increased cleavage of CXCL1 protein]; Chondroitin Sulfates promotes the reaction [CTSL protein results in increased cleavage of CXCL1 protein]; Chondroitin Sulfates promotes the reaction [CTSS protein results in increased cleavage of CXCL1 protein] |
CTD |
PMID:25833952 |
|
NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
multiple interactions |
ISO |
Chondroitin Sulfates inhibits the reaction [CTSB protein results in increased degradation of CXCL9 protein] |
CTD |
PMID:25833952 |
|
NCBI chr14:17,228,832...17,233,743
Ensembl chr14:17,228,856...17,234,712
|
|
G |
F12 |
coagulation factor XII |
increases activity |
ISO |
Chondroitin Sulfates analog results in increased activity of F12 protein |
CTD |
PMID:18434646 |
|
NCBI chr17:9,736,577...9,744,420
Ensembl chr17:9,736,577...9,744,420
|
|
G |
Fgf10 |
fibroblast growth factor 10 |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF10 protein; Chondroitin Sulfates analog binds to FGF10 protein |
CTD |
PMID:12221095 PMID:15385557 |
|
NCBI chr 2:51,673,480...51,747,533
Ensembl chr 2:51,672,722...51,750,369
|
|
G |
Fgf16 |
fibroblast growth factor 16 |
affects binding |
EXP |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF16 protein; Chondroitin Sulfates analog binds to FGF16 protein |
CTD |
PMID:12221095 PMID:15385557 |
|
NCBI chr X:76,786,728...76,796,311
Ensembl chr X:76,786,466...76,797,069
|
|
G |
Fgf18 |
fibroblast growth factor 18 |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF18 protein; Chondroitin Sulfates analog binds to FGF18 protein |
CTD |
PMID:12221095 PMID:15385557 |
|
NCBI chr10:18,047,109...18,082,290
Ensembl chr10:18,047,109...18,063,391
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF2 protein; Chondroitin Sulfates analog binds to FGF2 protein |
CTD |
PMID:12221095 PMID:15385557 |
|
NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
|
|
G |
Fgf23 |
fibroblast growth factor 23 |
increases activity |
ISO |
Chondroitin Sulfates analog results in increased activity of FGF23 protein |
CTD |
PMID:16081635 |
|
NCBI chr 4:159,622,404...159,630,082
Ensembl chr 4:159,622,404...159,630,082
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to GDNF protein |
CTD |
PMID:15385557 |
|
NCBI chr 2:56,884,181...56,912,964
Ensembl chr 2:56,887,987...56,910,238
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to HBEGF protein; Chondroitin Sulfates analog binds to HBEGF protein |
CTD |
PMID:12221095 PMID:15385557 |
|
NCBI chr18:29,330,302...29,340,185
Ensembl chr18:29,329,764...29,340,403
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of NOS2 protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGES protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGS2 protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in increased expression of TIMP3 mRNA; [Glucosamine co-treated with Chondroitin Sulfates] inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; [Glucosamine co-treated with Chondroitin Sulfates] inhibits the reaction [IL1B protein results in increased secretion of Nitrites] |
CTD |
PMID:17605605 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Itih1 |
inter-alpha trypsin inhibitor, heavy chain 1 |
multiple interactions |
ISO |
TNFAIP6 protein promotes the reaction [ITIH1 protein binds to Chondroitin Sulfates] |
CTD |
PMID:25561734 |
|
NCBI chr16:7,012,376...7,026,542
Ensembl chr16:7,012,354...7,026,540
|
|
G |
Klkb1 |
kallikrein B1 |
increases activity |
ISO |
Chondroitin Sulfates analog results in increased activity of KLKB1 protein |
CTD |
PMID:18434646 |
|
NCBI chr16:50,151,127...50,175,407
Ensembl chr16:50,152,008...50,175,458
|
|
G |
Mdk |
midkine |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to MDK protein; Chondroitin Sulfates analog binds to MDK protein |
CTD |
PMID:12221095 PMID:15385557 |
|
NCBI chr 3:80,841,003...80,843,895
Ensembl chr 3:80,841,005...80,842,916
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions |
ISO |
[Glucosamine co-treated with Chondroitin Sulfates] results in decreased expression of MMP3 mRNA; [Glucosamine co-treated with Chondroitin Sulfates] results in decreased secretion of MMP3 protein |
CTD |
PMID:20110869 |
|
NCBI chr 8:5,676,608...5,698,579
Ensembl chr 8:5,676,665...5,698,579
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
[Chondroitin Sulfates co-treated with Hyaluronic Acid] inhibits the reaction [Carbon Tetrachloride results in increased activity of MPO protein] |
CTD |
PMID:14697411 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
[Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of NFKB1 protein] |
CTD |
PMID:17879260 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in decreased expression of NFKBIA protein] |
CTD |
PMID:17879260 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of NOS2 protein |
CTD |
PMID:17605605 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
multiple interactions |
ISO |
Chondroitin Sulfates promotes the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of PDGFRB protein]; Genistein inhibits the reaction [Chondroitin Sulfates promotes the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of PDGFRB protein]] |
CTD |
PMID:16945567 |
|
NCBI chr 7:121,215,458...121,233,092
Ensembl chr 7:121,214,628...121,232,741
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
multiple interactions |
ISO |
Chondroitin Sulfates promotes the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of PDGFRB protein]; Genistein inhibits the reaction [Chondroitin Sulfates promotes the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of PDGFRB protein]] |
CTD |
PMID:16945567 |
|
NCBI chr18:56,364,586...56,406,381
Ensembl chr18:56,364,620...56,406,381
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions |
ISO |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGES protein |
CTD |
PMID:17605605 |
|
NCBI chr 3:9,727,408...9,738,752
Ensembl chr 3:9,727,408...9,738,752
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGS2 protein |
CTD |
PMID:17605605 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Ptn |
pleiotrophin |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to PTN protein; Chondroitin Sulfates analog binds to PTN protein |
CTD |
PMID:12221095 PMID:15385557 |
|
NCBI chr 4:64,239,156...64,330,996
Ensembl chr 4:64,239,158...64,330,996
|
|
G |
Ptpn11 |
protein tyrosine phosphatase, non-receptor type 11 |
affects binding |
ISO |
PTPN11 protein binds to Chondroitin Sulfates |
CTD |
PMID:29794138 |
|
NCBI chr12:40,895,515...40,955,999
Ensembl chr12:40,895,515...40,955,999
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of RELA protein] |
CTD |
PMID:17879260 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Timp3 |
TIMP metallopeptidase inhibitor 3 |
multiple interactions |
ISO |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in increased expression of TIMP3 mRNA |
CTD |
PMID:17605605 |
|
NCBI chr 7:23,543,125...23,594,170
Ensembl chr 7:23,544,215...23,594,133
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
[Chondroitin Sulfates co-treated with Hyaluronic Acid] inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein] [Glucosamine co-treated with Chondroitin Sulfates] results in decreased expression of TNF |
CTD |
PMID:14697411 PMID:20110869 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
multiple interactions |
ISO |
TNFAIP6 protein promotes the reaction [ITIH1 protein binds to Chondroitin Sulfates] |
CTD |
PMID:25561734 |
|
NCBI chr 3:37,545,238...37,564,704
Ensembl chr 3:37,545,238...37,564,699
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
multiple interactions increases expression |
ISO |
[Chondroitin Sulfates co-treated with Cholecalciferol] results in increased expression of TNFRSF11B mRNA; [Chondroitin Sulfates co-treated with Cholecalciferol] results in increased expression of TNFRSF11B protein; [Chondroitin Sulfates co-treated with Glucosamine co-treated with Cholecalciferol] results in increased expression of TNFRSF11B mRNA; [Chondroitin Sulfates co-treated with Glucosamine co-treated with Cholecalciferol] results in increased expression of TNFRSF11B protein; [Chondroitin Sulfates co-treated with Glucosamine] results in increased expression of TNFRSF11B mRNA; [Chondroitin Sulfates co-treated with Glucosamine] results in increased expression of TNFRSF11B protein Chondroitin Sulfates results in increased expression of TNFRSF11B protein |
CTD |
PMID:17996099 |
|
NCBI chr 7:93,798,580...93,826,586
Ensembl chr 7:93,798,545...93,826,665
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions decreases expression |
ISO |
[Chondroitin Sulfates co-treated with Glucosamine] inhibits the reaction [Cholecalciferol results in increased expression of TNFSF11 mRNA]; Chondroitin Sulfates inhibits the reaction [Cholecalciferol results in increased expression of TNFSF11 mRNA]; Chondroitin Sulfates inhibits the reaction [Glucosamine results in increased expression of TNFSF11 mRNA] Chondroitin Sulfates results in decreased expression of TNFSF11 mRNA |
CTD |
PMID:17996099 |
|
NCBI chr15:60,482,527...60,512,704
Ensembl chr15:60,482,527...60,512,704
|
|
G |
Vegfa |
vascular endothelial growth factor A |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to VEGFA protein |
CTD |
PMID:15385557 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to BDNF protein |
CTD |
PMID:15385557 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
F2 |
coagulation factor II |
multiple interactions |
ISO |
[Dermatan Sulfate co-treated with SERPIND1 protein] results in decreased activity of F2 protein |
CTD |
PMID:11805133 |
|
NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031
|
|
G |
Fgf10 |
fibroblast growth factor 10 |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF10 protein |
CTD |
PMID:15385557 |
|
NCBI chr 2:51,673,480...51,747,533
Ensembl chr 2:51,672,722...51,750,369
|
|
G |
Fgf16 |
fibroblast growth factor 16 |
affects binding |
EXP |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF16 protein |
CTD |
PMID:15385557 |
|
NCBI chr X:76,786,728...76,796,311
Ensembl chr X:76,786,466...76,797,069
|
|
G |
Fgf18 |
fibroblast growth factor 18 |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF18 protein |
CTD |
PMID:15385557 |
|
NCBI chr10:18,047,109...18,082,290
Ensembl chr10:18,047,109...18,063,391
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
affects binding increases activity |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF2 protein Dermatan Sulfate analog results in increased activity of FGF2 protein |
CTD |
PMID:15385557 PMID:15563459 |
|
NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
|
|
G |
Fgf23 |
fibroblast growth factor 23 |
increases activity |
ISO |
Dermatan Sulfate analog results in increased activity of FGF23 protein |
CTD |
PMID:16081635 |
|
NCBI chr 4:159,622,404...159,630,082
Ensembl chr 4:159,622,404...159,630,082
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
increases activity |
ISO |
Dermatan Sulfate analog results in increased activity of FGF7 protein |
CTD |
PMID:15563459 |
|
NCBI chr 3:118,315,859...118,368,464
Ensembl chr 3:118,317,761...118,366,872
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to GDNF protein |
CTD |
PMID:15385557 |
|
NCBI chr 2:56,884,181...56,912,964
Ensembl chr 2:56,887,987...56,910,238
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to HBEGF protein |
CTD |
PMID:15385557 |
|
NCBI chr18:29,330,302...29,340,185
Ensembl chr18:29,329,764...29,340,403
|
|
G |
Mdk |
midkine |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to MDK protein |
CTD |
PMID:15385557 |
|
NCBI chr 3:80,841,003...80,843,895
Ensembl chr 3:80,841,005...80,842,916
|
|
G |
Pdgfra |
platelet derived growth factor receptor alpha |
decreases expression |
ISO |
Dermatan Sulfate results in decreased expression of PDGFRA mRNA |
CTD |
PMID:16945567 |
|
NCBI chr14:35,527,926...35,581,130
Ensembl chr14:35,527,927...35,581,031
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
decreases expression |
ISO |
Dermatan Sulfate results in decreased expression of PDGFRB mRNA |
CTD |
PMID:16945567 |
|
NCBI chr18:56,364,586...56,406,381
Ensembl chr18:56,364,620...56,406,381
|
|
G |
Ptn |
pleiotrophin |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to PTN protein |
CTD |
PMID:15385557 |
|
NCBI chr 4:64,239,156...64,330,996
Ensembl chr 4:64,239,158...64,330,996
|
|
G |
Serpind1 |
serpin family D member 1 |
multiple interactions |
ISO |
[Dermatan Sulfate co-treated with SERPIND1 protein] results in decreased activity of F2 protein |
CTD |
PMID:11805133 |
|
NCBI chr11:87,913,814...87,924,880
Ensembl chr11:87,913,806...87,924,816
|
|
G |
Vegfa |
vascular endothelial growth factor A |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to VEGFA protein |
CTD |
PMID:15385557 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
Heparitin Sulfate inhibits the reaction [Hydrogen Peroxide results in increased degradation of [CCL5 protein binds to CCL5 protein]]; Heparitin Sulfate inhibits the reaction [Hydrogen Peroxide results in increased degradation of CCL5 protein] |
CTD |
PMID:21963154 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions |
ISO |
CXCL10 protein inhibits the reaction [CXCL1 protein binds to Heparitin Sulfate] |
CTD |
PMID:12549928 |
|
NCBI chr14:18,743,678...18,745,457
Ensembl chr14:18,743,685...18,745,457
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
CXCL10 protein inhibits the reaction [CXCL1 protein binds to Heparitin Sulfate] |
CTD |
PMID:12549928 |
|
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
CXCL10 protein inhibits the reaction [CXCL1 protein binds to Heparitin Sulfate] |
CTD |
PMID:12549928 |
|
NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
affects binding |
ISO |
FGF1 protein binds to Heparitin Sulfate binds to FGFR1 protein |
CTD |
PMID:12604602 |
|
NCBI chr18:32,273,830...32,359,831
Ensembl chr18:32,273,770...32,359,824
|
|
G |
Fgf10 |
fibroblast growth factor 10 |
affects activity |
ISO |
Heparitin Sulfate affects the activity of FGF10 protein |
CTD |
PMID:12781692 PMID:12818887 |
|
NCBI chr 2:51,673,480...51,747,533
Ensembl chr 2:51,672,722...51,750,369
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions affects binding increases activity |
ISO |
Heparitin Sulfate binds to and affects the activity of FGF2 protein Heparitin Sulfate binds to FGF2 protein Heparitin Sulfate analog results in increased activity of FGF2 protein |
CTD |
PMID:12460940 PMID:15464572 PMID:15958608 |
|
NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
|
|
G |
Fgf4 |
fibroblast growth factor 4 |
affects binding |
ISO |
Heparitin Sulfate binds to FGF4 protein |
CTD |
PMID:15769253 |
|
NCBI chr 1:218,024,537...218,029,539
Ensembl chr 1:218,025,810...218,027,220
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
affects binding |
ISO |
Heparitin Sulfate binds to FGF7 protein |
CTD |
PMID:15769253 |
|
NCBI chr 3:118,315,859...118,368,464
Ensembl chr 3:118,317,761...118,366,872
|
|
G |
Fgf8 |
fibroblast growth factor 8 |
affects binding increases activity |
ISO |
Heparitin Sulfate binds to FGF8 protein alternative form Heparitin Sulfate analog results in increased activity of FGF8 protein |
CTD |
PMID:12460940 PMID:15769253 |
|
NCBI chr 1:265,492,949...265,498,965
Ensembl chr 1:265,493,124...265,498,831
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
affects binding increases activity |
ISO |
FGF1 protein binds to Heparitin Sulfate binds to FGFR1 protein Heparitin Sulfate analog results in increased activity of FGFR1 protein alternative form |
CTD |
PMID:12460940 PMID:12604602 |
|
NCBI chr16:71,265,390...71,319,046
Ensembl chr16:71,266,248...71,319,449
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
decreases activity |
ISO |
Heparitin Sulfate analog results in decreased activity of FGFR2 protein mutant form |
CTD |
PMID:16373332 |
|
NCBI chr 1:200,590,951...200,696,946
Ensembl chr 1:200,590,953...200,696,928
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
increases activity |
ISO |
Heparitin Sulfate analog results in increased activity of FGFR3 protein alternative form |
CTD |
PMID:12460940 |
|
NCBI chr14:82,272,322...82,287,739
Ensembl chr14:82,273,070...82,287,706
|
|
G |
Fgfr4 |
fibroblast growth factor receptor 4 |
affects binding |
ISO |
Heparitin Sulfate analog binds to FGFR4 protein |
CTD |
PMID:11278860 |
|
NCBI chr17:9,990,072...10,004,339
Ensembl chr17:9,990,078...10,004,321
|
|
G |
Gns |
glucosamine (N-acetyl)-6-sulfatase |
affects degradation |
ISO |
GNS affects the degradation of Heparitin Sulfate |
CTD |
PMID:3391615 |
|
NCBI chr 7:63,467,027...63,501,054
Ensembl chr 7:63,467,216...63,499,353
|
|
G |
Gpc1 |
glypican 1 |
affects binding multiple interactions |
ISO |
GPC1 protein binds to Heparitin Sulfate GPC1 protein modified form results in increased cleavage of [GPC1 protein binds to Heparitin Sulfate]; nitroxyl affects the reaction [GPC1 protein results in increased cleavage of [GPC1 protein binds to Heparitin Sulfate]]; Zinc affects the reaction [GPC1 protein results in increased cleavage of [GPC1 protein binds to Heparitin Sulfate]] |
CTD |
PMID:12732622 |
|
NCBI chr 9:99,998,275...100,026,818
Ensembl chr 9:99,998,275...100,026,818
|
|
G |
Hpse |
heparanase |
multiple interactions decreases abundance affects abundance |
ISO EXP |
[Heparin results in decreased activity of HPSE protein] which affects the abundance of Heparitin Sulfate; [phosphomannopentaose sulfate results in decreased activity of HPSE protein] which affects the abundance of Heparitin Sulfate HPSE protein results in decreased abundance of Heparitin Sulfate HPSE protein affects the abundance of Heparitin Sulfate |
CTD |
PMID:16899518 PMID:17121850 |
|
NCBI chr14:10,534,358...10,576,686
Ensembl chr14:10,534,423...10,575,224
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Heparitin Sulfate inhibits the reaction [[NDST1 protein co-treated with NDST2 protein] affects the phosphorylation of MAPK1 protein] |
CTD |
PMID:19937756 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Heparitin Sulfate inhibits the reaction [[NDST1 protein co-treated with NDST2 protein] affects the phosphorylation of MAPK3 protein] |
CTD |
PMID:19937756 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Ndst1 |
N-deacetylase and N-sulfotransferase 1 |
multiple interactions |
ISO |
Heparitin Sulfate affects the susceptibility to [NDST1 protein co-treated with NDST2 protein]; Heparitin Sulfate inhibits the reaction [[NDST1 protein co-treated with NDST2 protein] affects the phosphorylation of MAPK1 protein]; Heparitin Sulfate inhibits the reaction [[NDST1 protein co-treated with NDST2 protein] affects the phosphorylation of MAPK3 protein] |
CTD |
PMID:19937756 |
|
NCBI chr18:55,951,497...56,014,107
Ensembl chr18:55,955,389...55,992,885
|
|
G |
Ndst2 |
N-deacetylase and N-sulfotransferase 2 |
multiple interactions |
ISO |
Heparitin Sulfate affects the susceptibility to [NDST1 protein co-treated with NDST2 protein]; Heparitin Sulfate inhibits the reaction [[NDST1 protein co-treated with NDST2 protein] affects the phosphorylation of MAPK1 protein]; Heparitin Sulfate inhibits the reaction [[NDST1 protein co-treated with NDST2 protein] affects the phosphorylation of MAPK3 protein] |
CTD |
PMID:19937756 |
|
NCBI chr15:3,995,797...4,006,491
Ensembl chr15:3,996,048...4,006,491
|
|
G |
Prnp |
prion protein |
affects binding |
ISO |
PRNP protein modified form binds to Heparitin Sulfate metabolite |
CTD |
PMID:18717736 |
|
NCBI chr 3:124,515,917...124,531,320
Ensembl chr 3:124,515,978...124,531,316
|
|
G |
Timp3 |
TIMP metallopeptidase inhibitor 3 |
multiple interactions |
ISO |
[N6L peptide binds to Heparitin Sulfate] which results in increased secretion of TIMP3 protein |
CTD |
PMID:23109338 |
|
NCBI chr 7:23,543,125...23,594,170
Ensembl chr 7:23,544,215...23,594,133
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
Heparitin Sulfate promotes the reaction [Dipyridamole results in increased secretion of VEGFA protein] |
CTD |
PMID:20067761 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
affects activity multiple interactions |
ISO |
Heparin affects the activity of ABCC1 protein Heparin affects the reaction [ABCC1 protein affects the transport of Doxorubicin] |
CTD |
PMID:17352253 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Ackr3 |
atypical chemokine receptor 3 |
multiple interactions |
EXP |
Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ACKR3 mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr 9:97,355,881...97,367,455
Ensembl chr 9:97,355,924...97,367,445
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
Heparin analog inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] |
CTD |
PMID:16904936 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Actr3 |
actin related protein 3 |
increases expression |
EXP |
Heparin results in increased expression of ACTR3 protein |
CTD |
PMID:17488504 |
|
NCBI chr13:41,695,520...41,738,622
Ensembl chr13:41,695,183...41,738,658
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
multiple interactions |
EXP |
Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ADAMTS1 mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr11:25,342,119...25,350,938
Ensembl chr11:25,342,126...25,350,974
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
Heparin inhibits the reaction [AGT protein affects the localization of Calcium] |
CTD |
PMID:21613610 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
Heparin inhibits the reaction [FGF1 protein results in increased phosphorylation of AKT1 protein]; Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:14966081 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Anxa6 |
annexin A6 |
increases expression |
EXP |
Heparin results in increased expression of ANXA6 protein |
CTD |
PMID:17488504 |
|
NCBI chr10:40,320,581...40,375,605
Ensembl chr10:40,320,581...40,375,605
|
|
G |
Apcs |
amyloid P component, serum |
increases expression |
ISO |
Heparin results in increased expression of APCS protein |
CTD |
PMID:17162433 |
|
NCBI chr13:91,426,621...91,427,417
Ensembl chr13:91,426,479...91,427,575
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
Copper promotes the reaction [Heparin binds to APP protein]; Zinc promotes the reaction [Heparin binds to APP protein] |
CTD |
PMID:25835329 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
increases expression |
EXP |
Heparin results in increased expression of ARHGDIA protein |
CTD |
PMID:17488504 |
|
NCBI chr10:109,754,012...109,757,506
Ensembl chr10:109,754,004...109,757,550
|
|
G |
Atp1b1 |
ATPase Na+/K+ transporting subunit beta 1 |
multiple interactions |
EXP |
Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ATP1B1 mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr13:82,737,161...82,757,681
Ensembl chr13:82,737,159...82,758,004
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
Heparin results in increased expression of BAX protein Heparin inhibits the reaction [arsenite results in increased expression of BAX protein] |
CTD |
PMID:11787776 PMID:26677073 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression multiple interactions |
ISO |
Heparin results in increased expression of BCL2 protein Heparin inhibits the reaction [arsenite results in decreased expression of BCL2 protein] |
CTD |
PMID:11787776 PMID:15205081 PMID:15671997 PMID:26677073 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions decreases expression |
ISO |
Heparin inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]; Heparin inhibits the reaction [BMP6 protein results in increased secretion of HAMP protein modified form] Heparin results in decreased expression of BMP6 mRNA |
CTD |
PMID:25633564 |
|
NCBI chr17:26,955,142...27,112,820
Ensembl chr17:26,955,142...27,112,820
|
|
G |
Bmpr1a |
bone morphogenetic protein receptor type 1A |
decreases expression |
ISO |
Heparin results in decreased expression of BMPR1A mRNA |
CTD |
PMID:25633564 |
|
NCBI chr16:10,758,278...10,852,170
Ensembl chr16:10,758,527...10,802,512
|
|
G |
C3 |
complement C3 |
decreases expression |
ISO |
Heparin results in decreased expression of C3 protein |
CTD |
PMID:7948777 PMID:10568115 |
|
NCBI chr 9:9,721,137...9,747,084
Ensembl chr 9:9,721,105...9,747,167
|
|
G |
C5 |
complement C5 |
decreases expression |
ISO |
Heparin results in decreased expression of C5 protein |
CTD |
PMID:7948777 |
|
NCBI chr 3:14,049,993...14,113,931 NCBI chr 3:14,206,466...14,229,141
Ensembl chr 3:14,049,995...14,229,080
|
|
G |
Cacna1e |
calcium voltage-gated channel subunit alpha1 E |
multiple interactions |
EXP |
Heparin affects the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]] |
CTD |
PMID:12663092 |
|
NCBI chr13:71,899,445...72,534,992
Ensembl chr13:71,906,702...72,367,980
|
|
G |
Capg |
capping actin protein, gelsolin like |
increases expression |
EXP |
Heparin results in increased expression of CAPG protein |
CTD |
PMID:17488504 |
|
NCBI chr 4:100,395,693...100,419,447
Ensembl chr 4:100,407,658...100,419,446
|
|
G |
Casp12 |
caspase 12 |
multiple interactions |
ISO |
Heparin inhibits the reaction [Paraoxon results in increased expression of CASP12 protein] |
CTD |
PMID:20079824 |
|
NCBI chr 8:2,658,892...2,686,160
Ensembl chr 8:2,659,865...2,686,160
|
|
G |
Casp3 |
caspase 3 |
decreases activity multiple interactions |
ISO EXP |
Heparin results in decreased activity of CASP3 protein Heparin promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]; Lithium Chloride inhibits the reaction [Heparin promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]] |
CTD |
PMID:16556679 PMID:30377735 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cat |
catalase |
increases activity |
ISO |
Heparin results in increased activity of CAT protein |
CTD |
PMID:12218949 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
affects binding multiple interactions |
ISO |
Heparin binds to CCL11 protein Heparin inhibits the reaction [PLG protein affects the degradation of CCL11 protein] |
CTD |
PMID:17384413 |
|
NCBI chr10:69,434,965...69,439,566
Ensembl chr10:69,434,941...69,439,575
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
EXP |
Heparin results in decreased expression of CCL2 protein |
CTD |
PMID:11053056 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Cd40lg |
CD40 ligand |
decreases expression |
ISO |
Heparin results in decreased expression of CD40LG protein |
CTD |
PMID:16391376 |
|
NCBI chr X:159,703,703...159,714,886
Ensembl chr X:159,703,578...159,716,562
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
EXP |
Heparin results in increased expression of CDKN1A protein |
CTD |
PMID:10926548 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases expression increases expression |
ISO |
Heparin analog results in decreased expression of CDKN1B protein Heparin analog results in increased expression of CDKN1B protein |
CTD |
PMID:18057711 PMID:20201787 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Col18a1 |
collagen type XVIII alpha 1 chain |
affects binding |
ISO |
Heparin binds to COL18A1 protein alternative form |
CTD |
PMID:15604266 |
|
NCBI chr20:12,225,202...12,332,858
Ensembl chr20:12,225,202...12,332,858
|
|
G |
Crp |
C-reactive protein |
increases expression |
ISO |
Heparin results in increased expression of CRP protein |
CTD |
PMID:16391376 |
|
NCBI chr13:91,080,448...91,081,358
Ensembl chr13:91,054,974...91,093,713
|
|
G |
Csf3 |
colony stimulating factor 3 |
multiple interactions |
EXP |
Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of CSF3 mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr10:86,616,785...86,619,160
Ensembl chr10:86,616,785...86,619,157
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
EXP |
Heparin promotes the reaction [Doxorubicin results in decreased expression of CTNNB1 protein]; Lithium Chloride inhibits the reaction [Heparin promotes the reaction [Doxorubicin results in decreased expression of CTNNB1 protein]] |
CTD |
PMID:30377735 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
EXP |
Heparin inhibits the reaction [endotoxin, Escherichia coli results in increased expression of CXCL10 mRNA] |
CTD |
PMID:31813902 |
|
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression |
ISO |
Heparin analog results in decreased expression of CXCL12 mRNA; Heparin analog results in decreased expression of CXCL12 protein |
CTD |
PMID:20201787 |
|
NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
EXP |
Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of CXCL2 mRNA]; Heparin inhibits the reaction [Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of CXCL2 protein]] |
CTD |
PMID:16401727 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
decreases expression |
ISO |
Heparin analog results in decreased expression of CXCR4 mRNA; Heparin analog results in decreased expression of CXCR4 protein |
CTD |
PMID:20201787 |
|
NCBI chr13:45,314,952...45,318,856
Ensembl chr13:45,314,933...45,318,878
|
|
G |
Ddah2 |
dimethylarginine dimethylaminohydrolase 2 |
decreases expression |
EXP |
Heparin results in decreased expression of DDAH2 protein |
CTD |
PMID:17488504 |
|
NCBI chr20:5,049,260...5,052,573
Ensembl chr20:5,049,496...5,052,585
|
|
G |
Des |
desmin |
decreases expression |
EXP |
Heparin results in decreased expression of DES protein |
CTD |
PMID:9111513 |
|
NCBI chr 9:82,556,574...82,564,288
Ensembl chr 9:82,556,573...82,564,294
|
|
G |
E2f1 |
E2F transcription factor 1 |
decreases expression |
ISO |
Heparin analog results in decreased expression of E2F1 protein |
CTD |
PMID:20201787 |
|
NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions decreases expression decreases secretion |
ISO EXP |
Heparin inhibits the reaction [F2 protein results in increased expression of EDN1 mRNA]; Heparin inhibits the reaction [F2 protein results in increased secretion of EDN1 protein] Heparin results in decreased expression of EDN1 mRNA Heparin inhibits the reaction [EDN1 protein results in increased abundance of Calcium]; Heparin inhibits the reaction [EDN1 protein results in increased abundance of Inositol 1,4,5-Trisphosphate] Heparin results in decreased secretion of EDN1 protein |
CTD |
PMID:1443220 PMID:7509996 PMID:8408661 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Egf |
epidermal growth factor |
decreases activity |
ISO |
Heparin results in decreased activity of EGF protein |
CTD |
PMID:12714831 |
|
NCBI chr 2:68,820,616...68,895,537
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression increases phosphorylation |
ISO |
Heparin results in decreased expression of EGFR mRNA; Heparin results in decreased expression of EGFR protein Heparin results in increased phosphorylation of EGFR protein |
CTD |
PMID:16475731 PMID:16556679 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Egln3 |
egl-9 family hypoxia-inducible factor 3 |
multiple interactions |
EXP |
Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of EGLN3 mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr 6:75,050,329...75,075,795
Ensembl chr 6:75,050,329...75,075,795
|
|
G |
F10 |
coagulation factor X |
decreases activity |
ISO EXP |
Heparin results in decreased activity of F10 protein |
CTD |
PMID:8950779 |
|
NCBI chr16:81,803,169...81,822,476
Ensembl chr16:81,803,110...81,822,716
|
|
G |
F2 |
coagulation factor II |
multiple interactions decreases expression increases expression |
ISO |
F2 protein promotes the reaction [Heparin results in increased abundance of Nitric Oxide]; Heparin deficiency results in increased cleavage of and results in increased activity of F2 protein; Heparin deficiency results in increased expression of [SERPINC1 protein binds to F2 protein]; Heparin inhibits the reaction [F2 protein affects the localization of SELP protein]; Heparin inhibits the reaction [F2 protein results in increased cleavage of F2R protein]; Heparin inhibits the reaction [F2 protein results in increased expression of EDN1 mRNA]; Heparin inhibits the reaction [F2 protein results in increased secretion of EDN1 protein] Heparin results in increased expression of [F2 protein binds to SERPINC1 protein] Heparin results in decreased expression of F2 protein Heparin deficiency results in increased expression of F2 protein; Heparin results in increased expression of F2 protein |
CTD |
PMID:7509996 PMID:7895349 PMID:8408661 PMID:9740346 PMID:11869846 PMID:16391376 PMID:16961586 PMID:19468011 |
|
NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031
|
|
G |
F2r |
coagulation factor II (thrombin) receptor |
multiple interactions |
ISO |
Heparin inhibits the reaction [F2 protein results in increased cleavage of F2R protein] |
CTD |
PMID:19468011 |
|
NCBI chr 2:26,118,760...26,135,340
Ensembl chr 2:26,118,760...26,135,340
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
Heparin results in increased expression of FAS protein |
CTD |
PMID:15205081 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Fcgr2a |
Fc fragment of IgG receptor IIa |
affects binding |
ISO |
[Heparin binds to PF4 protein] which binds to FCGR2A protein |
CTD |
PMID:8282825 |
|
NCBI chr13:91,146,878...91,163,691
Ensembl chr13:91,168,973...91,198,036 Ensembl chr13:91,168,973...91,198,036
|
|
G |
Fga |
fibrinogen alpha chain |
increases cleavage |
ISO |
Heparin deficiency results in increased cleavage of FGA protein |
CTD |
PMID:7895349 |
|
NCBI chr 2:181,997,562...182,013,726
Ensembl chr 2:182,006,242...182,013,763
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
multiple interactions affects binding |
ISO EXP |
[Heparin analog binds to FGFR2 protein alternative form] which binds to and results in increased activity of FGF1 protein; Heparin analog promotes the reaction [FGF1 protein binds to FGF1 protein] [Heparin binds to FGFR2 protein alternative form] which binds to FGF1 protein Heparin affects the reaction [FGF1 protein binds to FGFR4 protein]; Heparin inhibits the reaction [FGF1 protein results in increased phosphorylation of AKT1 protein]; Heparin inhibits the reaction [FGF1 protein results in increased phosphorylation of MAP2K1 protein]; Heparin inhibits the reaction [FGF1 protein results in increased phosphorylation of MAP2K2 protein]; Heparin inhibits the reaction [FGF1 protein results in increased phosphorylation of MAPK1 protein]; Heparin inhibits the reaction [FGF1 protein results in increased phosphorylation of MAPK3 protein]; Heparin promotes the reaction [FGF1 protein results in increased expression of FGF1 protein] Heparin promotes the reaction [FGFR1 protein binds to FGF1 protein]; Heparin promotes the reaction [FGFR3 protein binds to FGF1 protein] |
CTD |
PMID:1379594 PMID:8576258 PMID:10336501 PMID:10860838 PMID:14966081 PMID:16219767 |
|
NCBI chr18:32,273,830...32,359,831
Ensembl chr18:32,273,770...32,359,824
|
|
G |
Fgf10 |
fibroblast growth factor 10 |
multiple interactions |
ISO |
Heparin promotes the reaction [FGF10 protein binds to FGFR2 protein] |
CTD |
PMID:15632068 |
|
NCBI chr 2:51,673,480...51,747,533
Ensembl chr 2:51,672,722...51,750,369
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
affects binding multiple interactions |
ISO |
Heparin binds to FGF19 protein Heparin promotes the reaction [FGF19 protein binds to FGFR4 protein] |
CTD |
PMID:10525310 PMID:14730967 |
|
NCBI chr 1:218,058,405...218,061,693
Ensembl chr 1:218,058,405...218,061,693
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
affects binding decreases expression multiple interactions affects activity |
ISO EXP |
Heparin binds to FGF2 protein; Heparin binds to FGFR1 protein binds to FGF2 protein Heparin results in decreased expression of FGF2 protein [Heparin binds to FGFR2 protein alternative form] which binds to FGF2 protein Heparin affects the reaction [FGF2 protein binds to FGFR4 protein]; Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of AKT1 protein]; Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of MAP2K1 protein]; Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of MAP2K2 protein]; Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]; Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein] Heparin affects the activity of FGF2 protein Heparin promotes the reaction [FGFR1 protein binds to FGF2 protein]; Heparin promotes the reaction [FGFR2 protein binds to FGF2 protein] |
CTD |
PMID:1373495 PMID:1379594 PMID:8441232 PMID:10336501 PMID:10860838 PMID:14966081 PMID:15096041 PMID:15232299 PMID:17524524 |
|
NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
|
|
G |
Fgf23 |
fibroblast growth factor 23 |
increases activity |
ISO |
Heparin analog results in increased activity of FGF23 protein |
CTD |
PMID:16081635 |
|
NCBI chr 4:159,622,404...159,630,082
Ensembl chr 4:159,622,404...159,630,082
|
|
G |
Fgf3 |
fibroblast growth factor 3 |
affects activity |
ISO |
Heparin affects the activity of FGF3 protein |
CTD |
PMID:7592624 |
|
NCBI chr 1:218,003,018...218,006,942
Ensembl chr 1:218,003,018...218,006,942
|
|
G |
Fgf4 |
fibroblast growth factor 4 |
multiple interactions |
ISO |
Heparin binds to and results in increased activity of FGF4 protein |
CTD |
PMID:11486033 |
|
NCBI chr 1:218,024,537...218,029,539
Ensembl chr 1:218,025,810...218,027,220
|
|
G |
Fgf5 |
fibroblast growth factor 5 |
affects activity |
ISO |
Heparin affects the activity of FGF5 protein |
CTD |
PMID:8386828 |
|
NCBI chr14:12,974,921...12,996,046
Ensembl chr14:12,974,921...12,995,584
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
affects binding |
EXP |
[Heparin binds to FGFR2 protein alternative form] which binds to FGF7 protein |
CTD |
PMID:10860838 |
|
NCBI chr 3:118,315,859...118,368,464
Ensembl chr 3:118,317,761...118,366,872
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
affects binding multiple interactions |
ISO |
Heparin binds to FGFR1 protein binds to FGF2 protein Heparin promotes the reaction [FGFR1 protein binds to FGF1 protein]; Heparin promotes the reaction [FGFR1 protein binds to FGF2 protein] |
CTD |
PMID:1379594 PMID:15096041 |
|
NCBI chr16:71,265,390...71,319,046
Ensembl chr16:71,266,248...71,319,449
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
multiple interactions affects binding affects activity |
ISO EXP |
[Heparin analog binds to FGFR2 protein alternative form] which binds to and results in increased activity of FGF1 protein; Heparin promotes the reaction [FGF10 protein binds to FGFR2 protein] [Heparin binds to FGFR2 protein alternative form] which binds to FGF1 protein; [Heparin binds to FGFR2 protein alternative form] which binds to FGF2 protein; [Heparin binds to FGFR2 protein alternative form] which binds to FGF7 protein Heparin promotes the reaction [FGFR2 protein binds to FGF2 protein] Heparin affects the activity of FGFR2 protein |
CTD |
PMID:1373495 PMID:10860838 PMID:15632068 PMID:16219767 |
|
NCBI chr 1:200,590,951...200,696,946
Ensembl chr 1:200,590,953...200,696,928
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
affects activity multiple interactions |
ISO |
Heparin affects the activity of FGFR3 protein Heparin promotes the reaction [FGFR3 protein binds to FGF1 protein] |
CTD |
PMID:1379594 |
|
NCBI chr14:82,272,322...82,287,739
Ensembl chr14:82,273,070...82,287,706
|
|
G |
Fgfr4 |
fibroblast growth factor receptor 4 |
affects binding multiple interactions |
ISO EXP |
Heparin analog binds to FGFR4 protein Heparin affects the reaction [FGF1 protein binds to FGFR4 protein]; Heparin affects the reaction [FGF2 protein binds to FGFR4 protein] Heparin promotes the reaction [FGF19 protein binds to FGFR4 protein]; Heparin promotes the reaction [FGFR4 protein binds to FGFR4 protein] |
CTD |
PMID:10336501 PMID:10525310 PMID:10736564 PMID:11278860 |
|
NCBI chr17:9,990,072...10,004,339
Ensembl chr17:9,990,078...10,004,321
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression decreases expression multiple interactions |
ISO EXP |
Heparin results in increased expression of FOS protein Heparin results in decreased expression of FOS mRNA Heparin inhibits the reaction [4-O-methyl-12-O-tetradecanoylphorbol 13-acetate results in increased expression of FOS mRNA] |
CTD |
PMID:2099192 PMID:9083085 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Gata4 |
GATA binding protein 4 |
multiple interactions |
EXP |
Heparin inhibits the reaction [Inositol 1,4,5-Trisphosphate results in increased expression of GATA4 protein] |
CTD |
PMID:16259952 |
|
NCBI chr15:46,386,703...46,458,679
Ensembl chr15:46,386,712...46,432,965
|
|
G |
Gns |
glucosamine (N-acetyl)-6-sulfatase |
affects degradation |
ISO |
GNS affects the degradation of Heparin |
CTD |
PMID:3391615 |
|
NCBI chr 7:63,467,027...63,501,054
Ensembl chr 7:63,467,216...63,499,353
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
Heparin inhibits the reaction [Diclofenac promotes the reaction [endotoxin, Escherichia coli results in increased activity of GPT protein]] |
CTD |
PMID:31813902 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gzmb |
granzyme B |
multiple interactions |
EXP |
Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of GZMB mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr15:35,413,862...35,417,293
Ensembl chr15:35,413,793...35,417,316
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
decreases expression decreases secretion multiple interactions |
ISO |
Heparin results in decreased expression of HAMP mRNA Heparin results in decreased secretion of HAMP protein modified form Heparin inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]; Heparin inhibits the reaction [BMP6 protein results in increased secretion of HAMP protein modified form]; Heparin inhibits the reaction [IL6 protein results in increased expression of HAMP mRNA] |
CTD |
PMID:25633564 PMID:25686467 |
|
NCBI chr 1:89,368,021...89,369,960
Ensembl chr 1:89,368,021...89,369,960
|
|
G |
Hgf |
hepatocyte growth factor |
multiple interactions affects binding increases expression |
ISO |
Heparin promotes the reaction [HGF protein binds to and results in increased activity of MET protein] HGF protein binds to Heparin Heparin results in increased expression of HGF protein |
CTD |
PMID:9083085 PMID:18243369 |
|
NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
Heparin inhibits the reaction [endotoxin, Escherichia coli results in increased expression of HMOX1 mRNA] |
CTD |
PMID:31813902 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hpse |
heparanase |
multiple interactions |
ISO |
[Heparin results in decreased activity of HPSE protein] which affects the abundance of Heparitin Sulfate |
CTD |
PMID:17121850 |
|
NCBI chr14:10,534,358...10,576,686
Ensembl chr14:10,534,423...10,575,224
|
|
G |
Hrg |
histidine-rich glycoprotein |
multiple interactions |
ISO |
Heparin inhibits the reaction [Zinc results in increased activity of HRG protein] |
CTD |
PMID:8690451 |
|
NCBI chr11:81,621,274...81,639,938
Ensembl chr11:81,621,283...81,639,952
|
|
G |
Igsf10 |
immunoglobulin superfamily, member 10 |
multiple interactions |
EXP |
Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of IGSF10 mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr 2:149,535,199...149,564,180
Ensembl chr 2:149,533,151...149,564,113
|
|
G |
Il6 |
interleukin 6 |
increases expression increases secretion multiple interactions |
ISO EXP |
Heparin results in increased expression of IL6 protein Heparin analog results in increased secretion of IL6 protein Heparin inhibits the reaction [IL6 protein results in increased expression of HAMP mRNA] Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of IL6 mRNA] |
CTD |
PMID:16391376 PMID:16401727 PMID:25633564 PMID:26476401 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Itgam |
integrin subunit alpha M |
decreases expression increases expression |
ISO |
Heparin results in decreased expression of ITGAM protein Heparin results in increased expression of ITGAM protein |
CTD |
PMID:8595612 PMID:8993250 |
|
NCBI chr 1:199,495,312...199,545,738
Ensembl chr 1:199,495,298...199,623,960
|
|
G |
Itgax |
integrin subunit alpha X |
decreases expression |
ISO |
Heparin results in decreased expression of ITGAX protein |
CTD |
PMID:8993250 |
|
NCBI chr 1:199,555,560...199,576,948
Ensembl chr 1:199,555,722...199,576,932
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Heparin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of JUN protein] |
CTD |
PMID:1730747 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Klf4 |
Kruppel like factor 4 |
multiple interactions |
EXP |
Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of KLF4 mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr 5:72,283,311...72,287,669
Ensembl chr 5:72,283,313...72,287,669
|
|
G |
Krt18 |
keratin 18 |
increases expression |
ISO |
Heparin results in increased expression of KRT18 protein |
CTD |
PMID:15671997 |
|
NCBI chr 7:143,629,455...143,633,131
Ensembl chr 7:143,629,455...143,633,131
|
|
G |
Ldhb |
lactate dehydrogenase B |
decreases expression |
EXP |
Heparin results in decreased expression of LDHB protein |
CTD |
PMID:17488504 |
|
NCBI chr 4:176,701,980...176,719,999
Ensembl chr 4:176,701,983...176,720,012
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
EXP |
[etofibrate co-treated with Heparin] results in increased secretion of LPL protein |
CTD |
PMID:3179329 |
|
NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
EXP |
Heparin inhibits the reaction [FGF1 protein results in increased phosphorylation of MAP2K1 protein]; Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of MAP2K1 protein] |
CTD |
PMID:14966081 |
|
NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
multiple interactions |
EXP |
Heparin inhibits the reaction [FGF1 protein results in increased phosphorylation of MAP2K2 protein]; Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of MAP2K2 protein] |
CTD |
PMID:14966081 |
|
NCBI chr 7:11,458,971...11,478,520
Ensembl chr 7:11,458,967...11,478,489
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases activity |
ISO EXP |
Heparin analog inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein] Heparin inhibits the reaction [sodium chlorate results in decreased phosphorylation of MAPK1 protein] Heparin inhibits the reaction [FGF1 protein results in increased phosphorylation of MAPK1 protein]; Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein] Heparin results in increased activity of MAPK1 protein |
CTD |
PMID:14966081 PMID:16556679 PMID:18057711 PMID:19937756 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases activity |
ISO EXP |
Heparin analog inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein] Heparin inhibits the reaction [sodium chlorate results in decreased phosphorylation of MAPK3 protein] Heparin inhibits the reaction [FGF1 protein results in increased phosphorylation of MAPK3 protein]; Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein] Heparin results in increased activity of MAPK3 protein |
CTD |
PMID:14966081 PMID:16556679 PMID:18057711 PMID:19937756 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
ISO |
Heparin promotes the reaction [MAPT protein binds to MAPT protein]; Mercuric Chloride promotes the reaction [Heparin promotes the reaction [MAPT protein binds to MAPT protein]] |
CTD |
PMID:20665688 PMID:31678113 |
|
NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
multiple interactions |
ISO |
Heparin promotes the reaction [HGF protein binds to and results in increased activity of MET protein] |
CTD |
PMID:9083085 |
|
NCBI chr 4:44,747,467...44,854,628
Ensembl chr 4:44,774,741...44,852,665
|
|
G |
Mif |
macrophage migration inhibitory factor |
affects binding |
ISO |
MIF protein binds to Heparin |
CTD |
PMID:26852939 |
|
NCBI chr20:13,715,219...13,732,980
Ensembl chr20:13,732,198...13,732,859
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
decreases activity |
ISO |
Heparin results in decreased activity of MMP1 protein |
CTD |
PMID:10958381 |
|
NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
decreases expression |
ISO |
Heparin analog results in decreased expression of MMP14 mRNA |
CTD |
PMID:26476401 |
|
NCBI chr15:33,074,441...33,083,666
Ensembl chr15:33,074,441...33,083,655
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases activity |
ISO |
Heparin results in decreased activity of MMP2 protein |
CTD |
PMID:10958381 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases activity increases expression multiple interactions |
ISO |
Heparin results in decreased activity of MMP9 protein Heparin results in increased expression of MMP9 mRNA; Heparin results in increased expression of MMP9 protein Heparin results in increased metabolism of and results in increased activity of MMP9 protein |
CTD |
PMID:10958381 PMID:14630814 PMID:16190367 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Msn |
moesin |
increases expression |
EXP |
Heparin results in increased expression of MSN protein |
CTD |
PMID:17488504 |
|
NCBI chr X:65,226,834...65,294,192
Ensembl chr X:65,226,748...65,295,810
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression decreases expression |
ISO EXP |
Heparin results in increased expression of MYC protein Heparin results in decreased expression of MYC mRNA |
CTD |
PMID:2099192 PMID:11787776 PMID:16475731 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Nfatc3 |
nuclear factor of activated T-cells 3 |
multiple interactions |
EXP |
Heparin inhibits the reaction [Inositol 1,4,5-Trisphosphate results in increased expression of NFATC3 protein] |
CTD |
PMID:16259952 |
|
NCBI chr19:38,039,542...38,114,003
Ensembl chr19:38,039,564...38,114,003
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
increases expression |
ISO |
Heparin analog results in increased expression of NFE2L2 mRNA |
CTD |
PMID:26476401 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Park7 |
Parkinsonism associated deglycase |
increases expression |
EXP |
Heparin results in increased expression of PARK7 protein |
CTD |
PMID:17488504 |
|
NCBI chr 5:167,982,438...168,004,724
Ensembl chr 5:167,982,439...168,004,724
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
EXP |
Heparin promotes the reaction [Doxorubicin results in increased cleavage of PARP1 protein] |
CTD |
PMID:30377735 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
affects expression |
EXP |
Heparin affects the expression of PDGFB protein |
CTD |
PMID:8441232 |
|
NCBI chr 7:121,215,458...121,233,092
Ensembl chr 7:121,214,628...121,232,741
|
|
G |
Pdgfra |
platelet derived growth factor receptor alpha |
decreases expression |
ISO |
Heparin results in decreased expression of PDGFRA mRNA |
CTD |
PMID:16945567 |
|
NCBI chr14:35,527,926...35,581,130
Ensembl chr14:35,527,927...35,581,031
|
|
G |
Pdhb |
pyruvate dehydrogenase E1 subunit beta |
decreases expression |
EXP |
Heparin results in decreased expression of PDHB protein |
CTD |
PMID:17488504 |
|
NCBI chr15:18,540,826...18,546,855
Ensembl chr15:18,539,210...18,546,854
|
|
G |
Pf4 |
platelet factor 4 |
affects binding increases secretion |
ISO |
[Heparin binds to PF4 protein] which binds to FCGR2A protein; Heparin binds to PF4 protein Heparin results in increased secretion of PF4 protein |
CTD |
PMID:2437338 PMID:2709525 PMID:8282825 PMID:20162249 |
|
NCBI chr14:18,848,549...18,849,258
Ensembl chr14:18,848,549...18,849,258
|
|
G |
Pitpna |
phosphatidylinositol transfer protein, alpha |
increases expression |
EXP |
Heparin results in increased expression of PITPNA protein |
CTD |
PMID:17488504 |
|
NCBI chr10:63,731,767...63,772,049
Ensembl chr10:63,731,767...63,772,049
|
|
G |
Plat |
plasminogen activator, tissue type |
increases expression |
ISO |
Heparin results in increased expression of PLAT mRNA; Heparin results in increased expression of PLAT protein |
CTD |
PMID:14630814 PMID:16190367 |
|
NCBI chr16:74,098,263...74,122,897
Ensembl chr16:74,098,260...74,122,889
|
|
G |
Plau |
plasminogen activator, urokinase |
decreases expression |
ISO |
Heparin analog results in decreased expression of PLAU mRNA |
CTD |
PMID:26476401 |
|
NCBI chr15:3,644,296...3,650,765
Ensembl chr15:3,644,769...3,650,819
|
|
G |
Plg |
plasminogen |
multiple interactions |
ISO |
Heparin inhibits the reaction [PLG protein affects the degradation of CCL11 protein] |
CTD |
PMID:17384413 |
|
NCBI chr 1:48,521,828...48,563,895
Ensembl chr 1:48,521,772...48,563,776
|
|
G |
Ppbp |
pro-platelet basic protein |
increases secretion |
ISO |
Heparin results in increased secretion of PPBP protein |
CTD |
PMID:2437338 |
|
NCBI chr14:18,852,433...18,853,237
Ensembl chr14:18,851,954...18,853,315
|
|
G |
Proc |
protein C, inactivator of coagulation factors Va and VIIIa |
increases activity |
ISO |
Heparin deficiency results in increased activity of PROC protein |
CTD |
PMID:7895349 |
|
NCBI chr18:24,918,402...24,928,822
Ensembl chr18:24,918,398...24,929,091
|
|
G |
Psmb5 |
proteasome 20S subunit beta 5 |
decreases activity decreases expression |
ISO |
Heparin analog results in decreased activity of PSMB5 protein Heparin analog results in decreased expression of PSMB5 mRNA |
CTD |
PMID:26476401 |
|
NCBI chr15:33,259,039...33,263,634
Ensembl chr15:33,259,043...33,263,659
|
|
G |
Psmb6 |
proteasome 20S subunit beta 6 |
decreases expression |
ISO |
Heparin analog results in decreased expression of PSMB6 mRNA |
CTD |
PMID:26476401 |
|
NCBI chr10:57,131,339...57,133,685
Ensembl chr10:57,131,386...57,133,637
|
|
G |
Psmb7 |
proteasome 20S subunit beta 7 |
decreases expression |
ISO |
Heparin analog results in decreased expression of PSMB7 mRNA |
CTD |
PMID:26476401 |
|
NCBI chr 3:22,890,072...22,951,718
Ensembl chr 3:22,871,105...22,952,063
|
|
G |
Psme1 |
proteasome activator subunit 1 |
increases expression |
EXP |
Heparin results in increased expression of PSME1 protein |
CTD |
PMID:17488504 |
|
NCBI chr15:34,256,071...34,258,947
Ensembl chr15:34,256,071...34,258,947
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of PTGS2 mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
decreases phosphorylation |
ISO |
Heparin results in decreased phosphorylation of PTK2 protein |
CTD |
PMID:18674534 |
|
NCBI chr 7:114,436,419...114,611,317
Ensembl chr 7:114,437,361...114,590,119
|
|
G |
Pxn |
paxillin |
decreases phosphorylation |
ISO |
Heparin results in decreased phosphorylation of PXN protein |
CTD |
PMID:18674534 |
|
NCBI chr12:46,797,953...46,845,107
Ensembl chr12:46,797,954...46,845,080
|
|
G |
Rac1 |
Rac family small GTPase 1 |
multiple interactions |
EXP |
Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of RAC1 mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr12:13,090,316...13,111,841
Ensembl chr12:13,090,172...13,111,873
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
Heparin analog results in decreased expression of and results in decreased phosphorylation of RB1 protein |
CTD |
PMID:20201787 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Heparin inhibits the reaction [arsenite affects the localization of RELA protein]; Heparin inhibits the reaction [TNF protein affects the localization of RELA protein] |
CTD |
PMID:10843908 PMID:26677073 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
S100a1 |
S100 calcium binding protein A1 |
affects expression |
EXP |
Heparin affects the expression of S100A1 protein |
CTD |
PMID:12186470 |
|
NCBI chr 2:189,900,505...189,905,348
Ensembl chr 2:189,900,667...189,903,219
|
|
G |
S100a6 |
S100 calcium binding protein A6 |
affects expression increases expression |
EXP |
Heparin affects the expression of S100A6 protein Heparin results in increased expression of S100A6 protein |
CTD |
PMID:12186470 PMID:17488504 |
|
NCBI chr 2:190,007,013...190,008,512
Ensembl chr 2:190,007,216...190,008,511
|
|
G |
S100b |
S100 calcium binding protein B |
affects expression |
EXP |
Heparin affects the expression of S100B protein |
CTD |
PMID:12186470 |
|
NCBI chr20:13,130,633...13,142,856
Ensembl chr20:13,130,636...13,142,856
|
|
G |
Sdc1 |
syndecan 1 |
decreases expression |
ISO |
Heparin analog results in decreased expression of SDC1 mRNA |
CTD |
PMID:26476401 |
|
NCBI chr 6:33,885,576...33,908,038
Ensembl chr 6:33,885,495...33,908,016
|
|
G |
Sdc2 |
syndecan 2 |
decreases expression |
ISO |
Heparin analog results in decreased expression of SDC2 mRNA |
CTD |
PMID:26476401 |
|
NCBI chr 7:71,572,731...71,686,139
Ensembl chr 7:71,572,941...71,686,044
|
|
G |
Sdc4 |
syndecan 4 |
increases expression |
ISO |
Heparin analog results in increased expression of SDC4 mRNA |
CTD |
PMID:26476401 |
|
NCBI chr 3:160,872,503...160,891,190
Ensembl chr 3:160,872,503...160,891,190
|
|
G |
Sell |
selectin L |
decreases expression increases expression |
ISO |
Heparin results in decreased expression of SELL protein Heparin results in increased expression of SELL protein |
CTD |
PMID:8595612 PMID:8993250 |
|
NCBI chr13:82,369,820...82,387,774
Ensembl chr13:82,369,493...82,387,631
|
|
G |
Selp |
selectin P |
multiple interactions increases expression |
ISO |
Heparin inhibits the reaction [F2 protein affects the localization of SELP protein]; Heparin promotes the reaction [Adenosine Diphosphate affects the localization of SELP protein] Heparin results in increased expression of SELP protein |
CTD |
PMID:9740346 PMID:10544909 |
|
NCBI chr13:82,428,914...82,464,629
Ensembl chr13:82,429,063...82,464,628
|
|
G |
Septin2 |
septin 2 |
increases expression |
EXP |
Heparin results in increased expression of SEPTIN2 protein |
CTD |
PMID:17488504 |
|
NCBI chr 9:100,624,876...100,658,053
Ensembl chr 9:100,624,876...100,658,050
|
|
G |
Serpinc1 |
serpin family C member 1 |
decreases expression multiple interactions |
ISO |
Heparin deficiency results in decreased expression of SERPINC1 protein; Heparin results in decreased expression of SERPINC1 protein Heparin results in increased expression of [F2 protein binds to SERPINC1 protein] Heparin deficiency results in increased expression of [SERPINC1 protein binds to F2 protein] |
CTD |
PMID:73932 PMID:7895349 PMID:8122184 PMID:11869846 PMID:16961586 |
|
NCBI chr13:78,806,107...78,820,375
Ensembl chr13:78,805,347...78,833,192
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
EXP |
Heparin inhibits the reaction [Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of SERPINE1 protein]]; Heparin promotes the reaction [[Famotidine co-treated with Lipopolysaccharides] results in increased expression of SERPINE1 protein] |
CTD |
PMID:16401727 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Sfrp1 |
secreted frizzled-related protein 1 |
multiple interactions |
EXP |
Heparin promotes the reaction [Doxorubicin results in increased secretion of SFRP1 protein] |
CTD |
PMID:30377735 |
|
NCBI chr16:73,372,007...73,410,777
Ensembl chr16:73,372,007...73,410,777
|
|
G |
Slc5a3 |
solute carrier family 5 member 3 |
multiple interactions |
EXP |
Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SLC5A3 mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr11:32,229,366...32,231,812
|
|
G |
Slk |
STE20-like kinase |
multiple interactions |
EXP |
Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SLK mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr 1:267,359,761...267,415,735
Ensembl chr 1:267,359,830...267,412,810
|
|
G |
Stip1 |
stress-induced phosphoprotein 1 |
increases expression |
EXP |
Heparin results in increased expression of STIP1 protein |
CTD |
PMID:17488504 |
|
NCBI chr 1:222,274,133...222,293,139
Ensembl chr 1:222,274,133...222,293,148
|
|
G |
Tagln2 |
transgelin 2 |
decreases expression |
EXP |
Heparin results in decreased expression of TAGLN2 protein |
CTD |
PMID:17488504 |
|
NCBI chr13:90,807,196...90,814,119
Ensembl chr13:90,807,199...90,814,119
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions decreases expression |
EXP ISO |
Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of TFRC mRNA] Heparin results in decreased expression of TFRC protein |
CTD |
PMID:16401727 PMID:25633564 |
|
NCBI chr11:71,397,423...71,419,263
Ensembl chr11:71,397,383...71,419,223
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases expression |
EXP |
Heparin results in decreased expression of TGFB1 mRNA |
CTD |
PMID:15149336 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
ISO |
Heparin inhibits the reaction [TNF protein affects the localization of RELA protein] Heparin results in increased expression of TNF protein |
CTD |
PMID:10843908 PMID:17162433 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tp53 |
tumor protein p53 |
decreases expression |
ISO |
Heparin analog results in decreased expression of TP53 protein |
CTD |
PMID:20201787 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Vegfa |
vascular endothelial growth factor A |
affects binding |
ISO |
Heparin binds to VEGFA protein alternative form |
CTD |
PMID:20376344 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] |
CTD |
PMID:19047049 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
increases export multiple interactions |
ISO |
ABCC5 protein results in increased export of Hyaluronic Acid [Curcumin analog binds to and results in decreased activity of ABCC5 protein] which results in decreased export of Hyaluronic Acid; [Curcumin binds to and results in decreased activity of ABCC5 protein] which results in decreased export of Hyaluronic Acid; [xanthohumol binds to and results in decreased activity of ABCC5 protein] which results in decreased export of Hyaluronic Acid; Curcumin analog inhibits the reaction [ABCC5 protein results in increased export of Hyaluronic Acid]; Curcumin inhibits the reaction [ABCC5 protein results in increased export of Hyaluronic Acid]; xanthohumol inhibits the reaction [ABCC5 protein results in increased export of Hyaluronic Acid] |
CTD |
PMID:23978416 |
|
NCBI chr11:84,395,982...84,490,215
Ensembl chr11:84,396,033...84,490,211
|
|
G |
Abra |
actin-binding Rho activating protein |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ABRA protein] |
CTD |
PMID:23178681 |
|
NCBI chr 7:80,792,615...80,796,683
Ensembl chr 7:80,792,600...80,796,670
|
|
G |
Acan |
aggrecan |
multiple interactions |
ISO |
[Hyaluronic Acid co-treated with resveratrol] results in increased expression of ACAN mRNA |
CTD |
PMID:23595953 |
|
NCBI chr 1:140,762,758...140,824,441
Ensembl chr 1:140,762,758...140,824,441
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
multiple interactions decreases expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ACAT2 protein] Hyaluronic Acid analog results in decreased expression of ACAT2 protein |
CTD |
PMID:23178681 |
|
NCBI chr 1:47,972,399...47,992,654
Ensembl chr 1:47,972,399...47,992,653
|
|
G |
Aco2 |
aconitase 2 |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of ACO2 protein |
CTD |
PMID:23178681 |
|
NCBI chr 7:123,102,493...123,145,608
Ensembl chr 7:123,102,468...123,145,635
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
[CD44 protein affects the abundance of Hyaluronic Acid] affects the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:31285260 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Actb |
actin, beta |
multiple interactions affects expression |
EXP |
Hyaluronic Acid analog affects the reaction [Hydrogen Peroxide results in decreased expression of ACTB protein] Hyaluronic Acid analog affects the expression of ACTB protein |
CTD |
PMID:23178681 |
|
NCBI chr12:13,715,843...13,718,813
Ensembl chr12:13,715,843...13,718,841
|
|
G |
Actc1 |
actin, alpha, cardiac muscle 1 |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ACTC1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 3:105,507,403...105,512,939
Ensembl chr 3:105,507,403...105,512,939
|
|
G |
Actg2 |
actin gamma 2, smooth muscle |
multiple interactions decreases expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ACTG2 protein] Hyaluronic Acid analog results in decreased expression of ACTG2 protein |
CTD |
PMID:23178681 |
|
NCBI chr 4:115,215,160...115,239,746
Ensembl chr 4:115,215,060...115,239,723
|
|
G |
Actr3 |
actin related protein 3 |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ACTR3 protein] |
CTD |
PMID:23178681 |
|
NCBI chr13:41,695,520...41,738,622
Ensembl chr13:41,695,183...41,738,658
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Alb |
albumin |
increases abundance |
ISO |
ALB protein results in increased abundance of Hyaluronic Acid |
CTD |
PMID:16642209 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Anxa1 |
annexin A1 |
decreases expression multiple interactions |
EXP |
Hyaluronic Acid analog results in decreased expression of ANXA1 protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ANXA1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 1:237,893,983...237,910,002
Ensembl chr 1:237,893,966...237,910,012
|
|
G |
Anxa2 |
annexin A2 |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ANXA2 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 8:75,687,134...75,723,589
Ensembl chr 8:75,687,100...75,723,594
|
|
G |
Anxa3 |
annexin A3 |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of ANXA3 protein |
CTD |
PMID:23178681 |
|
NCBI chr14:14,371,921...14,426,503
Ensembl chr14:14,364,008...14,426,437
|
|
G |
Anxa4 |
annexin A4 |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ANXA4 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 4:118,538,775...118,595,591
Ensembl chr 4:118,538,777...118,595,580
|
|
G |
Anxa5 |
annexin A5 |
multiple interactions decreases expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ANXA5 protein] Hyaluronic Acid analog results in decreased expression of ANXA5 protein |
CTD |
PMID:23178681 |
|
NCBI chr 2:123,162,477...123,194,730
Ensembl chr 2:123,162,461...123,193,130
|
|
G |
Arhgap29 |
Rho GTPase activating protein 29 |
increases expression multiple interactions |
EXP |
Hyaluronic Acid analog results in increased expression of ARHGAP29 protein [Hyaluronic Acid analog co-treated with Hydrogen Peroxide] results in increased expression of ARHGAP29 protein |
CTD |
PMID:23178681 |
|
NCBI chr 2:225,552,075...225,613,349
Ensembl chr 2:225,552,148...225,613,359
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions increases cleavage |
EXP |
FG-4592 promotes the reaction [Hyaluronic Acid results in increased cleavage of ATG5 protein] |
CTD |
PMID:27082295 |
|
NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
|
|
G |
Atic |
5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase |
decreases expression multiple interactions |
EXP |
Hyaluronic Acid analog results in decreased expression of ATIC protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ATIC protein] |
CTD |
PMID:23178681 |
|
NCBI chr 9:78,862,013...78,882,061
Ensembl chr 9:78,862,013...78,882,060
|
|
G |
Atp5f1a |
ATP synthase F1 subunit alpha |
multiple interactions decreases expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ATP5F1A protein] Hyaluronic Acid analog results in decreased expression of ATP5F1A protein |
CTD |
PMID:23178681 |
|
NCBI chr18:74,156,553...74,164,490
Ensembl chr18:74,156,553...74,164,495
|
|
G |
Atp5f1b |
ATP synthase F1 subunit beta |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of ATP5F1B protein |
CTD |
PMID:23178681 |
|
NCBI chr 7:2,504,708...2,511,748
Ensembl chr 7:2,504,695...2,511,749
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 mRNA]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] |
CTD |
PMID:19047049 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression multiple interactions |
EXP |
Hyaluronic Acid results in increased expression of BNIP3 protein FG-4592 promotes the reaction [Hyaluronic Acid results in increased expression of BNIP3 protein] |
CTD |
PMID:27082295 |
|
NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
|
|
G |
Ca3 |
carbonic anhydrase 3 |
multiple interactions decreases expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of CAR3 protein] Hyaluronic Acid analog results in decreased expression of CAR3 protein |
CTD |
PMID:23178681 |
|
NCBI chr 2:88,126,519...88,136,063
Ensembl chr 2:88,126,667...88,135,410
|
|
G |
Calr |
calreticulin |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of CALR protein |
CTD |
PMID:23178681 |
|
NCBI chr19:25,956,771...25,961,666
Ensembl chr19:25,956,771...25,961,666
|
|
G |
Calu |
calumenin |
decreases expression multiple interactions |
EXP |
Hyaluronic Acid analog results in decreased expression of CALU protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of CALU protein] |
CTD |
PMID:23178681 |
|
NCBI chr 4:56,625,611...56,653,112
Ensembl chr 4:56,625,561...56,653,111
|
|
G |
Camk1 |
calcium/calmodulin-dependent protein kinase I |
multiple interactions decreases expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of CAMK1 protein] Hyaluronic Acid analog results in decreased expression of CAMK1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 4:145,289,300...145,300,146
Ensembl chr 4:145,288,996...145,300,177
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP3 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP3 mRNA] |
CTD |
PMID:17879260 PMID:19047049 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
[Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP7 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP7 mRNA] |
CTD |
PMID:17879260 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[Diclofenac co-treated with Hyaluronic Acid] results in increased activity of CASP8 protein |
CTD |
PMID:20237495 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased degradation of Hyaluronic Acid] |
CTD |
PMID:23692848 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases secretion |
ISO |
Hyaluronic Acid analog results in increased secretion of CCL5 protein |
CTD |
PMID:9278343 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Cct2 |
chaperonin containing TCP1 subunit 2 |
multiple interactions decreases expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of CCT2 protein] Hyaluronic Acid analog results in decreased expression of CCT2 protein |
CTD |
PMID:23178681 |
|
NCBI chr 7:60,106,532...60,122,779
Ensembl chr 7:60,109,974...60,122,805
|
|
G |
Cct4 |
chaperonin containing TCP1 subunit 4 |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of CCT4 protein] |
CTD |
PMID:23178681 |
|
NCBI chr14:107,767,392...107,780,270
Ensembl chr14:107,767,392...107,780,270
|
|
G |
Cct5 |
chaperonin containing TCP1 subunit 5 |
multiple interactions decreases expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of CCT5 protein] Hyaluronic Acid analog results in decreased expression of CCT5 protein |
CTD |
PMID:23178681 |
|
NCBI chr 2:84,667,578...84,678,730
Ensembl chr 2:84,667,633...84,678,790
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
multiple interactions increases expression affects binding |
ISO |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Doxorubicin; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Doxorubicin; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein; [[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein; [[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein; [CD44 protein affects the abundance of Hyaluronic Acid] affects the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; [Hyaluronic Acid analog binds to and results in increased activity of CD44 protein] which results in increased expression of PLAU mRNA; [Hyaluronic Acid analog binds to and results in increased activity of CD44 protein] which results in increased expression of PLAU protein; [Hyaluronic Acid analog binds to and results in increased activity of CD44 protein] which results in increased expression of PLAUR mRNA; [Hyaluronic Acid analog binds to and results in increased activity of CD44 protein] which results in increased expression of PLAUR protein; [Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein; Hyaluronic Acid analog binds to and results in increased activity of CD44 protein; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Doxorubicin]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Doxorubicin]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] Hyaluronic Acid analog affects the localization of [MAP3K1 protein binds to CD44 protein]; Hyaluronic Acid analog promotes the reaction [MAP3K1 protein binds to CD44 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [Hyaluronic Acid metabolite results in increased expression of CD44 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [Hyaluronic Acid metabolite results in increased expression of CD44 protein]; Tetradecanoylphorbol Acetate promotes the reaction [CD44 protein binds to Hyaluronic Acid]; Verapamil inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [CD44 protein binds to Hyaluronic Acid]] Hyaluronic Acid metabolite results in increased expression of CD44 mRNA; Hyaluronic Acid metabolite results in increased expression of CD44 protein |
CTD |
PMID:9929743 PMID:12402308 PMID:19047049 PMID:20159036 PMID:23692848 PMID:31285260 |
|
NCBI chr 3:92,695,083...92,783,820
Ensembl chr 3:92,696,313...92,783,658
|
|
G |
Cfl1 |
cofilin 1 |
multiple interactions decreases expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of CFL1 protein] Hyaluronic Acid analog results in decreased expression of CFL1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 1:220,869,805...220,873,337
Ensembl chr 1:220,869,805...220,873,337
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions |
ISO |
[Diclofenac co-treated with Hyaluronic Acid] results in decreased expression of CFLAR protein |
CTD |
PMID:20237495 |
|
NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
|
|
G |
Cftr |
CF transmembrane conductance regulator |
increases export multiple interactions |
ISO |
CFTR protein results in increased export of Hyaluronic Acid Curcumin analog inhibits the reaction [CFTR protein results in increased export of Hyaluronic Acid]; xanthohumol inhibits the reaction [CFTR protein results in increased export of Hyaluronic Acid] |
CTD |
PMID:23978416 |
|
NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676
|
|
G |
Cnn3 |
calponin 3 |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of CNN3 protein |
CTD |
PMID:23178681 |
|
NCBI chr 2:225,005,069...225,036,179
Ensembl chr 2:225,005,019...225,036,188
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions |
ISO |
[Hyaluronic Acid co-treated with resveratrol] results in increased expression of COL2A1 mRNA |
CTD |
PMID:23595953 |
|
NCBI chr 7:139,454,945...139,484,403
Ensembl chr 7:139,455,242...139,483,997
|
|
G |
Cops4 |
COP9 signalosome subunit 4 |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of COPS4 protein] |
CTD |
PMID:23178681 |
|
NCBI chr14:10,718,863...10,749,134
Ensembl chr14:10,718,844...10,749,120
|
|
G |
Coq7 |
coenzyme Q7, hydroxylase |
multiple interactions increases expression |
EXP |
[Hyaluronic Acid analog co-treated with Hydrogen Peroxide] affects the expression of COQ7 protein Hyaluronic Acid analog results in increased expression of COQ7 protein |
CTD |
PMID:23178681 |
|
NCBI chr 1:188,176,060...188,190,874
Ensembl chr 1:188,174,874...188,190,860
|
|
G |
Cpox |
coproporphyrinogen oxidase |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of CPOX protein] |
CTD |
PMID:23178681 |
|
NCBI chr11:44,039,665...44,049,648
Ensembl chr11:44,039,669...44,049,648
|
|
G |
Cth |
cystathionine gamma-lyase |
multiple interactions |
EXP |
[Hyaluronic Acid analog co-treated with Hydrogen Peroxide] results in decreased expression of CTH protein |
CTD |
PMID:23178681 |
|
NCBI chr 2:264,266,959...264,293,040
Ensembl chr 2:264,266,984...264,293,046
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Doxorubicin; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein; [[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Doxorubicin]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] |
CTD |
PMID:19047049 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
Hyaluronic Acid inhibits the reaction [Tobacco Smoke Pollution results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:30856093 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Dld |
dihydrolipoamide dehydrogenase |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of DLD protein |
CTD |
PMID:23178681 |
|
NCBI chr 6:50,597,677...50,618,694
Ensembl chr 6:50,597,677...50,618,694
|
|
G |
Dnaja1 |
DnaJ heat shock protein family (Hsp40) member A1 |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of DNAJA1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 5:57,028,467...57,039,378
Ensembl chr 5:57,028,467...57,039,378
|
|
G |
Dstn |
destrin, actin depolymerizing factor |
multiple interactions decreases expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of DSTN protein] Hyaluronic Acid analog results in decreased expression of DSTN protein |
CTD |
PMID:23178681 |
|
NCBI chr 3:138,024,508...138,051,304
Ensembl chr 3:138,024,508...138,051,298
|
|
G |
Eci2 |
enoyl-CoA delta isomerase 2 |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in increased expression of ECI2 protein] |
CTD |
PMID:23178681 |
|
NCBI chr17:30,556,926...30,573,324
Ensembl chr17:30,556,884...30,639,040
|
|
G |
Eef1g |
eukaryotic translation elongation factor 1 gamma |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of EEF1G protein] |
CTD |
PMID:23178681 |
|
NCBI chr 1:225,163,391...225,173,997
Ensembl chr 1:225,163,391...225,173,995
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
decreases expression multiple interactions |
EXP |
Hyaluronic Acid analog results in decreased expression of EEF2 protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of EEF2 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 7:11,401,501...11,406,771
Ensembl chr 7:11,401,501...11,406,771
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid] |
CTD |
PMID:21520325 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
increases phosphorylation |
ISO |
Hyaluronic Acid results in increased phosphorylation of EIF4E protein |
CTD |
PMID:16864594 |
|
NCBI chr 2:243,819,616...243,853,987
Ensembl chr 2:243,820,661...243,852,631
|
|
G |
Eno1 |
enolase 1 |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of ENO1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 5:167,288,223...167,299,610
Ensembl chr 5:167,288,223...167,299,609
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions |
ISO |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Doxorubicin; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Doxorubicin; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein; [[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein; [[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein; [Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Doxorubicin]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 mRNA]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Doxorubicin]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 mRNA]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 mRNA]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] |
CTD |
PMID:19047049 |
|
NCBI chr 7:122,818,194...122,889,055
Ensembl chr 7:122,818,975...122,861,296
|
|
G |
Erp29 |
endoplasmic reticulum protein 29 |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of ERP29 protein |
CTD |
PMID:23178681 |
|
NCBI chr12:40,619,377...40,625,884
Ensembl chr12:40,619,377...40,625,883
|
|
G |
Esd |
esterase D |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ESD protein] |
CTD |
PMID:23178681 |
|
NCBI chr15:56,756,848...56,776,348
Ensembl chr15:56,756,661...56,776,348
|
|
G |
Ezr |
ezrin |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of EZR protein] |
CTD |
PMID:23178681 |
|
NCBI chr 1:47,287,872...47,331,412
Ensembl chr 1:47,287,874...47,331,412
|
|
G |
Fgf23 |
fibroblast growth factor 23 |
increases activity |
ISO |
Hyaluronic Acid analog results in increased activity of FGF23 protein |
CTD |
PMID:16081635 |
|
NCBI chr 4:159,622,404...159,630,082
Ensembl chr 4:159,622,404...159,630,082
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
increases chemical synthesis |
EXP |
FGF7 protein results in increased chemical synthesis of Hyaluronic Acid |
CTD |
PMID:14506240 |
|
NCBI chr 3:118,315,859...118,368,464
Ensembl chr 3:118,317,761...118,366,872
|
|
G |
Fgg |
fibrinogen gamma chain |
increases expression multiple interactions |
EXP |
Hyaluronic Acid analog results in increased expression of FGG protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in increased expression of FGG protein] |
CTD |
PMID:23178681 |
|
NCBI chr 2:181,987,080...181,994,523
Ensembl chr 2:181,987,217...181,994,514
|
|
G |
Fkbp4 |
FKBP prolyl isomerase 4 |
decreases expression multiple interactions |
EXP |
Hyaluronic Acid analog results in decreased expression of FKBP4 protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of FKBP4 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 4:161,748,993...161,757,447
Ensembl chr 4:161,748,993...161,757,447
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
decreases expression multiple interactions |
EXP |
Hyaluronic Acid analog results in decreased expression of FSCN1 protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of FSCN1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr12:13,655,459...13,668,595
Ensembl chr12:13,656,554...13,668,515
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions increases chemical synthesis |
ISO |
[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased activity of [SMAD2 protein co-treated with SMAD3 protein]] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid]; [6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride results in decreased activity of SMAD3 protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid] |
CTD |
PMID:21520325 |
|
NCBI chr 3:98,088,321...98,092,131
Ensembl chr 3:98,088,324...98,092,131
|
|
G |
Fubp1 |
far upstream element binding protein 1 |
multiple interactions affects expression |
EXP |
[Hyaluronic Acid analog co-treated with Hydrogen Peroxide] results in increased expression of FUBP1 protein Hyaluronic Acid analog affects the expression of FUBP1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 2:257,425,676...257,452,745
Ensembl chr 2:257,425,679...257,449,568
|
|
G |
Gab1 |
GRB2-associated binding protein 1 |
increases phosphorylation |
ISO |
Hyaluronic Acid results in increased phosphorylation of GAB1 protein |
CTD |
PMID:16864594 |
|
NCBI chr19:30,794,290...30,903,819
Ensembl chr19:30,794,571...30,902,008
|
|
G |
Gdi1 |
GDP dissociation inhibitor 1 |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of GDI1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr X:156,400,734...156,407,396
Ensembl chr X:156,400,736...156,407,404
|
|
G |
Glrx3 |
glutaredoxin 3 |
decreases expression multiple interactions |
EXP |
Hyaluronic Acid analog results in decreased expression of GLRX3 protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of GLRX3 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 1:209,768,696...209,799,912
Ensembl chr 1:209,768,696...209,799,903
|
|
G |
Gnb1 |
G protein subunit beta 1 |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of GNB1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 5:172,914,025...172,981,403
Ensembl chr 5:172,934,990...172,979,986
|
|
G |
Gnb2 |
G protein subunit beta 2 |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of GNB2 protein] |
CTD |
PMID:23178681 |
|
NCBI chr12:22,229,079...22,234,096
Ensembl chr12:22,229,079...22,234,096
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of GOT1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 1:263,246,248...263,269,762
Ensembl chr 1:263,246,248...263,269,762
|
|
G |
Gsn |
gelsolin |
multiple interactions decreases expression |
EXP |
[Hyaluronic Acid analog co-treated with Hydrogen Peroxide] results in decreased expression of GSN protein Hyaluronic Acid analog results in decreased expression of GSN protein |
CTD |
PMID:23178681 |
|
NCBI chr 3:14,456,106...14,508,922
Ensembl chr 3:14,467,330...14,508,911
|
|
G |
Gucy2f |
guanylate cyclase 2F |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of GUCY2F protein] |
CTD |
PMID:23178681 |
|
NCBI chr X:113,372,240...113,474,210
Ensembl chr X:113,372,240...113,474,164
|
|
G |
Has1 |
hyaluronan synthase 1 |
increases expression |
ISO |
Hyaluronic Acid metabolite results in increased expression of HAS1 mRNA; Hyaluronic Acid metabolite results in increased expression of HAS1 protein |
CTD |
PMID:31226360 |
|
NCBI chr 1:59,720,612...59,732,409
Ensembl chr 1:59,720,612...59,732,409
|
|
G |
Has2 |
hyaluronan synthase 2 |
increases chemical synthesis affects abundance multiple interactions |
ISO |
HAS2 protein results in increased chemical synthesis of Hyaluronic Acid HAS2 protein affects the abundance of Hyaluronic Acid [IL1B protein results in increased expression of HAS2 protein] which results in increased chemical synthesis of Hyaluronic Acid |
CTD |
PMID:11318944 PMID:31285260 |
|
NCBI chr 7:96,438,046...96,464,049
Ensembl chr 7:96,438,046...96,464,049
|
|
G |
Has3 |
hyaluronan synthase 3 |
multiple interactions increases expression |
ISO |
[HAS3 protein affects the susceptibility to Carbon Tetrachloride] which affects the abundance of Hyaluronic Acid; HAS3 protein affects the reaction [Carbon Tetrachloride results in increased abundance of Hyaluronic Acid] Hyaluronic Acid metabolite results in increased expression of HAS3 mRNA; Hyaluronic Acid metabolite results in increased expression of HAS3 protein |
CTD |
PMID:27042213 PMID:31226360 |
|
NCBI chr19:39,063,298...39,077,745
Ensembl chr19:39,063,998...39,077,722
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression multiple interactions |
EXP |
Hyaluronic Acid results in increased expression of HIF1A protein FG-4592 promotes the reaction [Hyaluronic Acid results in increased expression of HIF1A protein] |
CTD |
PMID:27082295 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hmbs |
hydroxymethylbilane synthase |
multiple interactions decreases expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of HMBS protein] Hyaluronic Acid analog results in decreased expression of HMBS protein |
CTD |
PMID:23178681 |
|
NCBI chr 8:48,667,278...48,674,673
Ensembl chr 8:48,667,275...48,674,748
|
|
G |
Hmmr |
hyaluronan-mediated motility receptor |
multiple interactions |
ISO |
Hyaluronic Acid binds to and results in increased activity of HMMR protein |
CTD |
PMID:16864594 |
|
NCBI chr10:25,861,490...25,890,639
Ensembl chr10:25,861,490...25,890,639
|
|
G |
Hnrnpa2b1 |
heterogeneous nuclear ribonucleoprotein A2/B1 |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of HNRNPA2B1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 4:81,237,496...81,241,281
Ensembl chr 4:81,237,496...81,241,282
|
|
G |
Hnrnph1 |
heterogeneous nuclear ribonucleoprotein H1 |
multiple interactions decreases expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of HNRNPH1 protein] Hyaluronic Acid analog results in decreased expression of HNRNPH1 protein |
CTD |
PMID:23178681 |
|
NCBI chr10:35,872,619...35,879,911
Ensembl chr10:35,870,232...35,879,910
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of HNRNPK protein |
CTD |
PMID:23178681 |
|
NCBI chr17:6,664,730...6,676,753
Ensembl chr17:6,665,659...6,676,654
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of HSP90AA1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 6:135,107,262...135,112,793
Ensembl chr 6:135,107,271...135,112,775
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
decreases expression multiple interactions |
EXP |
Hyaluronic Acid analog results in decreased expression of HSP90B1 protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of HSP90B1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 7:27,226,570...27,240,533
Ensembl chr 7:27,226,569...27,240,533
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
affects expression multiple interactions |
EXP |
Hyaluronic Acid analog affects the expression of HSPA5 protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of HSPA5 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
multiple interactions decreases expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of HSPA8 protein] Hyaluronic Acid analog results in decreased expression of HSPA8 protein |
CTD |
PMID:23178681 |
|
NCBI chr 8:44,989,401...44,993,261
Ensembl chr 8:44,990,014...44,993,179
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of HSPB1 protein |
CTD |
PMID:23178681 |
|
NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of HSPD1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 9:61,680,529...61,691,202
Ensembl chr 9:61,680,530...61,690,956
|
|
G |
Idh1 |
isocitrate dehydrogenase (NADP(+)) 1 |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of IDH1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 9:71,882,108...71,911,645
Ensembl chr 9:71,882,105...71,900,044
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of IDH2 protein |
CTD |
PMID:23178681 |
|
NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
multiple interactions decreases expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of IDO1 protein] Hyaluronic Acid analog results in decreased expression of IDO1 protein |
CTD |
PMID:23178681 |
|
NCBI chr16:72,216,326...72,228,098
Ensembl chr16:72,216,326...72,228,098
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
Hyaluronic Acid inhibits the reaction [Acetaminophen results in increased expression of IFNG protein] |
CTD |
PMID:18237725 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il12b |
interleukin 12B |
increases secretion |
ISO |
Hyaluronic Acid analog results in increased secretion of IL12B protein |
CTD |
PMID:9278343 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il1b |
interleukin 1 beta |
increases abundance multiple interactions increases expression |
ISO |
IL1B protein results in increased abundance of Hyaluronic Acid [Hyaluronic Acid co-treated with resveratrol] results in decreased expression of IL1B mRNA Hyaluronic Acid metabolite results in increased expression of IL1B mRNA; Hyaluronic Acid metabolite results in increased expression of IL1B protein [acetic anhydride results in increased acetylation of Hyaluronic Acid metabolite] which results in increased secretion of IL1B protein; [Butyrates results in increased acylation of Hyaluronic Acid metabolite] inhibits the reaction [[Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of IL1B protein]; [Butyrates results in increased acylation of Hyaluronic Acid metabolite] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL1B protein]; [Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of IL1B protein; [IL1B protein results in increased expression of HAS2 protein] which results in increased chemical synthesis of Hyaluronic Acid; [Lipopolysaccharides results in decreased activity of TLR4 protein] inhibits the reaction [[Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of IL1B protein]; Sulindac inhibits the reaction [IL1B protein results in increased abundance of Hyaluronic Acid] |
CTD |
PMID:11318944 PMID:23595953 PMID:23692848 PMID:25053413 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[acetic anhydride results in increased acetylation of Hyaluronic Acid metabolite] which results in increased secretion of IL6 protein; [Butyrates results in increased acylation of Hyaluronic Acid metabolite] inhibits the reaction [[Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of IL6 protein]; [Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of IL6 protein |
CTD |
PMID:25053413 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Irak3 |
interleukin-1 receptor-associated kinase 3 |
increases expression |
ISO |
Hyaluronic Acid results in increased expression of IRAK3 protein |
CTD |
PMID:15728517 |
|
NCBI chr 7:64,922,830...64,982,224
Ensembl chr 7:64,923,615...64,982,281
|
|
G |
Itih1 |
inter-alpha trypsin inhibitor, heavy chain 1 |
multiple interactions |
ISO |
TNFAIP6 protein promotes the reaction [ITIH1 protein binds to Hyaluronic Acid] |
CTD |
PMID:25561734 |
|
NCBI chr16:7,012,376...7,026,542
Ensembl chr16:7,012,354...7,026,540
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases phosphorylation |
ISO |
Hyaluronic Acid analog results in increased phosphorylation of JUN protein |
CTD |
PMID:12402308 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Krt10 |
keratin 10 |
multiple interactions increases expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of KRT10 protein] Hyaluronic Acid analog results in increased expression of KRT10 protein |
CTD |
PMID:23178681 |
|
NCBI chr10:87,296,445...87,301,307
Ensembl chr10:87,296,451...87,300,736
|
|
G |
Lap3 |
leucine aminopeptidase 3 |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of LAP3 protein |
CTD |
PMID:23178681 |
|
NCBI chr14:70,102,813...70,121,797
Ensembl chr14:70,102,814...70,121,797
|
|
G |
Ldhb |
lactate dehydrogenase B |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of LDHB protein] |
CTD |
PMID:23178681 |
|
NCBI chr 4:176,701,980...176,719,999
Ensembl chr 4:176,701,983...176,720,012
|
|
G |
Lgals1 |
galectin 1 |
increases expression multiple interactions |
EXP |
Hyaluronic Acid analog results in increased expression of LGALS1 protein Hyaluronic Acid analog affects the reaction [Hydrogen Peroxide results in decreased expression of LGALS1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 7:120,153,184...120,156,290
Ensembl chr 7:120,153,184...120,156,289
|
|
G |
Lmna |
lamin A/C |
multiple interactions increases expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of LMNA protein] Hyaluronic Acid analog results in increased expression of LMNA protein |
CTD |
PMID:23178681 |
|
NCBI chr 2:187,842,884...187,863,552
Ensembl chr 2:187,842,885...187,863,516
|
|
G |
Lrpap1 |
LDL receptor related protein associated protein 1 |
multiple interactions decreases expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of LRPAP1 protein] Hyaluronic Acid analog results in decreased expression of LRPAP1 protein |
CTD |
PMID:23178681 |
|
NCBI chr14:80,911,281...80,923,290
Ensembl chr14:80,911,270...80,924,831
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions increases cleavage |
EXP |
FG-4592 promotes the reaction [Hyaluronic Acid results in increased cleavage of MAP1LC3B protein] |
CTD |
PMID:27082295 |
|
NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
increases phosphorylation |
ISO |
Hyaluronic Acid analog results in increased phosphorylation of MAP2K1 protein |
CTD |
PMID:12402308 |
|
NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
increases phosphorylation |
ISO |
Hyaluronic Acid analog results in increased phosphorylation of MAP2K2 protein |
CTD |
PMID:12402308 |
|
NCBI chr 7:11,458,971...11,478,520
Ensembl chr 7:11,458,967...11,478,489
|
|
G |
Map3k1 |
mitogen-activated protein kinase kinase kinase 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog affects the localization of [MAP3K1 protein binds to CD44 protein]; Hyaluronic Acid analog promotes the reaction [MAP3K1 protein binds to CD44 protein]; Hyaluronic Acid analog results in increased phosphorylation of and results in increased activity of MAP3K1 protein |
CTD |
PMID:20159036 |
|
NCBI chr 2:43,329,516...43,393,203
Ensembl chr 2:43,329,516...43,393,207
|
|
G |
Map3k3 |
mitogen activated protein kinase kinase kinase 3 |
multiple interactions |
ISO |
MAP3K3 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid] |
CTD |
PMID:20633555 |
|
NCBI chr10:94,280,703...94,349,372
Ensembl chr10:94,280,703...94,349,368
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Hyaluronic Acid analog results in increased phosphorylation of MAPK1 protein MAPK1 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid]; U 0126 inhibits the reaction [Hyaluronic Acid analog results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:12402308 PMID:20159036 PMID:20633555 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO |
Hyaluronic Acid analog results in increased phosphorylation of MAPK3 protein MAPK3 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid]; U 0126 inhibits the reaction [Hyaluronic Acid analog results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:12402308 PMID:20159036 PMID:20633555 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk7 |
mitogen-activated protein kinase 7 |
multiple interactions |
ISO |
MAPK7 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid] |
CTD |
PMID:20633555 |
|
NCBI chr10:47,768,592...47,775,130
Ensembl chr10:47,766,680...47,775,055
|
|
G |
Mfn1 |
mitofusin 1 |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of MFN1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 2:118,929,738...118,971,689
Ensembl chr 2:118,929,738...118,973,698
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions increases expression |
ISO |
[Hyaluronic Acid co-treated with resveratrol] results in decreased expression of MMP13 mRNA Hyaluronic Acid metabolite results in increased expression of MMP13 mRNA; Hyaluronic Acid metabolite results in increased expression of MMP13 protein |
CTD |
PMID:23595953 PMID:23692848 |
|
NCBI chr 8:5,522,739...5,533,018
Ensembl chr 8:5,522,739...5,533,018
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
affects activity |
ISO |
Hyaluronic Acid affects the activity of MMP2 protein |
CTD |
PMID:15597151 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions |
ISO |
[Hyaluronic Acid co-treated with resveratrol] results in decreased expression of MMP3 mRNA |
CTD |
PMID:23595953 |
|
NCBI chr 8:5,676,608...5,698,579
Ensembl chr 8:5,676,665...5,698,579
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
affects activity |
ISO |
Hyaluronic Acid affects the activity of MMP9 protein |
CTD |
PMID:15597151 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
[Chondroitin Sulfates co-treated with Hyaluronic Acid] inhibits the reaction [Carbon Tetrachloride results in increased activity of MPO protein] |
CTD |
PMID:14697411 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Mrps7 |
mitochondrial ribosomal protein S7 |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of MRPS7 protein |
CTD |
PMID:23178681 |
|
NCBI chr10:104,155,805...104,158,840
Ensembl chr10:104,155,805...104,158,839
|
|
G |
Mus81 |
MUS81 structure-specific endonuclease subunit |
multiple interactions decreases expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of MUS81 protein] Hyaluronic Acid analog results in decreased expression of MUS81 protein |
CTD |
PMID:23178681 |
|
NCBI chr 1:220,862,474...220,867,973
Ensembl chr 1:220,862,386...220,867,815
|
|
G |
Myl12a |
myosin light chain 12A |
multiple interactions decreases expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of MYL12A protein] Hyaluronic Acid analog results in decreased expression of MYL12A protein |
CTD |
PMID:23178681 |
|
NCBI chr 9:119,325,282...119,333,012
Ensembl chr 9:119,325,283...119,332,967
|
|
G |
Myl12b |
myosin light chain 12B |
decreases expression multiple interactions |
EXP |
Hyaluronic Acid analog results in decreased expression of MYL12B protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of MYL12B protein] |
CTD |
PMID:23178681 |
|
NCBI chr 9:119,307,168...119,321,500
Ensembl chr 9:119,307,176...119,321,500
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
Hyaluronic Acid metabolite results in increased activity of [NFKB1 protein binds to RELA protein] [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of NFKB1 protein] |
CTD |
PMID:17879260 PMID:23692848 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in decreased expression of NFKBIA protein] |
CTD |
PMID:17879260 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nme1 |
NME/NM23 nucleoside diphosphate kinase 1 |
decreases expression multiple interactions |
EXP |
Hyaluronic Acid analog results in decreased expression of NME1 protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of NME1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr10:81,657,152...81,666,542
Ensembl chr10:81,657,153...81,666,523
|
|
G |
Nme2 |
NME/NM23 nucleoside diphosphate kinase 2 |
multiple interactions decreases expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of NME2 protein] Hyaluronic Acid analog results in decreased expression of NME2 protein |
CTD |
PMID:23178681 |
|
NCBI chr10:81,648,216...81,653,717
Ensembl chr10:81,648,216...81,653,717
|
|
G |
Nos2 |
nitric oxide synthase 2 |
affects expression increases expression |
ISO |
Hyaluronic Acid affects the expression of NOS2 mRNA Hyaluronic Acid metabolite results in increased expression of NOS2 mRNA; Hyaluronic Acid metabolite results in increased expression of NOS2 protein |
CTD |
PMID:15597151 PMID:23692848 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nr1d1 |
nuclear receptor subfamily 1, group D, member 1 |
decreases expression |
ISO |
Hyaluronic Acid results in decreased expression of NR1D1 mRNA |
CTD |
PMID:17075855 |
|
NCBI chr10:86,683,875...86,690,815
Ensembl chr10:86,683,875...86,690,815
|
|
G |
Nrxn1 |
neurexin 1 |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of NRXN1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 6:13,886,757...15,191,660
Ensembl chr 6:13,886,740...15,191,660
|
|
G |
Optn |
optineurin |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of OPTN protein] |
CTD |
PMID:23178681 |
|
NCBI chr17:77,167,700...77,218,374
Ensembl chr17:77,167,740...77,218,389
|
|
G |
Pde4d |
phosphodiesterase 4D |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of PDE4D protein |
CTD |
PMID:23178681 |
|
NCBI chr 2:40,219,999...41,468,551
Ensembl chr 2:40,554,146...41,464,264
|
|
G |
Pdia3 |
protein disulfide isomerase family A, member 3 |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of PDIA3 protein |
CTD |
PMID:23178681 |
|
NCBI chr 3:113,376,983...113,400,707
Ensembl chr 3:113,376,983...113,400,707
|
|
G |
Pdia6 |
protein disulfide isomerase family A, member 6 |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of PDIA6 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 6:42,568,269...42,585,654
Ensembl chr 6:42,568,220...42,585,652
|
|
G |
Pgam1 |
phosphoglycerate mutase 1 |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of PGAM1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 1:261,158,204...261,165,814
Ensembl chr 1:261,158,261...261,165,808
|
|
G |
Pgk1 |
phosphoglycerate kinase 1 |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of PGK1 protein |
CTD |
PMID:23178681 |
|
NCBI chr X:77,263,399...77,279,373
Ensembl chr X:77,263,359...77,279,367
|
|
G |
Pgls |
6-phosphogluconolactonase |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of PGLS protein] |
CTD |
PMID:23178681 |
|
NCBI chr16:20,020,444...20,025,930
Ensembl chr16:20,020,444...20,025,930
|
|
G |
Phb |
prohibitin |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of PHB protein] |
CTD |
PMID:23178681 |
|
NCBI chr10:83,476,107...83,488,878
Ensembl chr10:83,476,107...83,488,878
|
|
G |
Phgdh |
phosphoglycerate dehydrogenase |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of PHGDH protein] |
CTD |
PMID:23178681 |
|
NCBI chr 2:200,484,245...200,513,564
Ensembl chr 2:200,484,246...200,513,564
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
increases phosphorylation |
ISO |
Hyaluronic Acid results in increased phosphorylation of PIK3CA protein |
CTD |
PMID:16864594 |
|
NCBI chr 2:118,831,350...118,861,456
Ensembl chr 2:118,831,350...118,861,454
|
|
G |
Pitpna |
phosphatidylinositol transfer protein, alpha |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of PITPNA protein] |
CTD |
PMID:23178681 |
|
NCBI chr10:63,731,767...63,772,049
Ensembl chr10:63,731,767...63,772,049
|
|
G |
Plau |
plasminogen activator, urokinase |
multiple interactions |
ISO |
[Hyaluronic Acid analog binds to and results in increased activity of CD44 protein] which results in increased expression of PLAU mRNA; [Hyaluronic Acid analog binds to and results in increased activity of CD44 protein] which results in increased expression of PLAU protein |
CTD |
PMID:12402308 |
|
NCBI chr15:3,644,296...3,650,765
Ensembl chr15:3,644,769...3,650,819
|
|
G |
Plaur |
plasminogen activator, urokinase receptor |
multiple interactions |
ISO |
[Hyaluronic Acid analog binds to and results in increased activity of CD44 protein] which results in increased expression of PLAUR mRNA; [Hyaluronic Acid analog binds to and results in increased activity of CD44 protein] which results in increased expression of PLAUR protein |
CTD |
PMID:12402308 |
|
NCBI chr 1:81,328,171...81,344,954
Ensembl chr 1:81,328,183...81,344,708
|
|
G |
Pls3 |
plastin 3 |
multiple interactions increases expression |
EXP |
[Hyaluronic Acid analog co-treated with Hydrogen Peroxide] results in increased expression of PLS3 protein Hyaluronic Acid analog results in increased expression of PLS3 protein |
CTD |
PMID:23178681 |
|
NCBI chr X:119,030,311...119,124,268
Ensembl chr X:119,030,419...119,124,250
|
|
G |
Ppia |
peptidylprolyl isomerase A |
multiple interactions decreases expression |
EXP |
[Hyaluronic Acid analog co-treated with Hydrogen Peroxide] results in decreased expression of PPIA protein Hyaluronic Acid analog results in decreased expression of PPIA protein |
CTD |
PMID:23178681 |
|
NCBI chr14:86,673,775...86,677,443
Ensembl chr14:86,673,775...86,677,443
|
|
G |
Ppp1ca |
protein phosphatase 1 catalytic subunit alpha |
multiple interactions |
EXP |
[Hyaluronic Acid analog co-treated with Hydrogen Peroxide] results in increased expression of PPP1CA protein |
CTD |
PMID:23178681 |
|
NCBI chr 1:219,439,953...219,443,570
Ensembl chr 1:219,439,953...219,443,570
|
|
G |
Prdx1 |
peroxiredoxin 1 |
affects expression |
EXP |
Hyaluronic Acid analog affects the expression of PRDX1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 5:135,536,413...135,551,986
Ensembl chr 5:135,536,413...135,551,990
|
|
G |
Prdx2 |
peroxiredoxin 2 |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of PRDX2 protein |
CTD |
PMID:23178681 |
|
NCBI chr19:26,084,816...26,090,095
Ensembl chr19:26,084,903...26,090,094
|
|
G |
Prdx6 |
peroxiredoxin 6 |
multiple interactions affects expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of PRDX6 protein] Hyaluronic Acid analog affects the expression of PRDX6 protein |
CTD |
PMID:23178681 |
|
NCBI chr13:79,077,567...79,088,113
Ensembl chr13:79,077,033...79,088,127
|
|
G |
Prph |
peripherin |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of PRPH protein |
CTD |
PMID:23178681 |
|
NCBI chr 7:140,742,406...140,746,197
Ensembl chr 7:140,742,418...140,746,197
|
|
G |
Psmb1 |
proteasome 20S subunit beta 1 |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in increased expression of PSMB1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 1:57,470,878...57,491,359
Ensembl chr 1:57,470,632...57,489,727
|
|
G |
Psmc2 |
proteasome 26S subunit, ATPase 2 |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of PSMC2 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 4:9,867,132...9,881,383
Ensembl chr 4:9,867,101...9,881,484
|
|
G |
Psmc4 |
proteasome 26S subunit, ATPase 4 |
multiple interactions decreases expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in increased expression of PSMC4 protein] Hyaluronic Acid analog results in decreased expression of PSMC4 protein |
CTD |
PMID:23178681 |
|
NCBI chr 1:84,978,220...84,986,536
Ensembl chr 1:84,978,206...84,986,581
|
|
G |
Psmc5 |
proteasome 26S subunit, ATPase 5 |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of PSMC5 protein |
CTD |
PMID:23178681 |
|
NCBI chr10:94,445,877...94,451,811
Ensembl chr10:94,445,877...94,451,811
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of PTK2 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 7:114,436,419...114,611,317
Ensembl chr 7:114,437,361...114,590,119
|
|
G |
Rack1 |
receptor for activated C kinase 1 |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of RACK1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr10:34,149,717...34,155,198
Ensembl chr10:34,149,717...34,155,198 Ensembl chr12:34,149,717...34,155,198
|
|
G |
Ran |
RAN, member RAS oncogene family |
multiple interactions decreases expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of RAN protein] Hyaluronic Acid analog results in decreased expression of RAN protein |
CTD |
PMID:23178681 |
|
NCBI chr12:31,319,556...31,324,105
Ensembl chr12:31,320,624...31,323,810
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases phosphorylation |
ISO |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Doxorubicin; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein; [[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of RELA protein]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Doxorubicin]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] Hyaluronic Acid metabolite results in increased phosphorylation of RELA protein Hyaluronic Acid metabolite results in increased activity of [NFKB1 protein binds to RELA protein] |
CTD |
PMID:17879260 PMID:19047049 PMID:23692848 PMID:31226360 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Renbp |
renin binding protein |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of RENBP protein] |
CTD |
PMID:23178681 |
|
NCBI chr X:156,854,490...156,863,548
Ensembl chr X:156,854,594...156,863,528
|
|
G |
Rock1 |
Rho-associated coiled-coil containing protein kinase 1 |
increases phosphorylation |
ISO |
Hyaluronic Acid results in increased phosphorylation of ROCK1 protein |
CTD |
PMID:16864594 |
|
NCBI chr18:1,273,490...1,390,790
Ensembl chr18:1,273,453...1,390,190
|
|
G |
Rps12 |
ribosomal protein S12 |
multiple interactions decreases expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of RPS12 protein] Hyaluronic Acid analog results in decreased expression of RPS12 protein |
CTD |
PMID:23178681 |
|
NCBI chr 1:22,758,214...22,760,370
Ensembl chr 1:22,758,212...22,760,370
|
|
G |
Scrn1 |
secernin 1 |
multiple interactions decreases expression |
EXP |
[Hyaluronic Acid analog co-treated with Hydrogen Peroxide] results in decreased expression of SCRN1 protein Hyaluronic Acid analog results in decreased expression of SCRN1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 4:84,678,978...84,740,701
Ensembl chr 4:84,678,975...84,740,909
|
|
G |
Septin11 |
septin 11 |
decreases expression multiple interactions |
EXP |
Hyaluronic Acid analog results in decreased expression of SEPTIN11 protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of SEPTIN11 protein] |
CTD |
PMID:23178681 |
|
NCBI chr14:16,369,544...16,405,645
Ensembl chr14:16,369,544...16,452,998
|
|
G |
Septin2 |
septin 2 |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of SEPTIN2 protein |
CTD |
PMID:23178681 |
|
NCBI chr 9:100,624,876...100,658,053
Ensembl chr 9:100,624,876...100,658,050
|
|
G |
Serpinh1 |
serpin family H member 1 |
multiple interactions affects expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of SERPINH1 protein] Hyaluronic Acid analog affects the expression of SERPINH1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 1:164,301,010...164,308,306
Ensembl chr 1:164,301,010...164,308,317
|
|
G |
Slc25a11 |
solute carrier family 25 member 11 |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of SLC25A11 protein |
CTD |
PMID:23178681 |
|
NCBI chr10:57,265,903...57,268,018
Ensembl chr10:57,265,704...57,268,081
|
|
G |
Slmap |
sarcolemma associated protein |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of SLMAP protein |
CTD |
PMID:23178681 |
|
NCBI chr16:2,112,271...2,227,336
Ensembl chr16:2,112,274...2,227,309
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions |
ISO |
[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased activity of [SMAD2 protein co-treated with SMAD3 protein]] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid] |
CTD |
PMID:21520325 |
|
NCBI chr18:72,550,107...72,612,078
Ensembl chr18:72,550,219...72,612,078
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions |
ISO |
[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased activity of [SMAD2 protein co-treated with SMAD3 protein]] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid]; [6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride results in decreased activity of SMAD3 protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid] |
CTD |
PMID:21520325 |
|
NCBI chr 8:68,569,530...68,678,349
Ensembl chr 8:68,569,530...68,678,349
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
increases expression |
ISO |
Hyaluronic Acid analog results in increased expression of SNAI2 mRNA; Hyaluronic Acid analog results in increased expression of SNAI2 protein |
CTD |
PMID:20159036 |
|
NCBI chr11:90,404,421...90,406,730
Ensembl chr11:90,403,333...90,406,797
|
|
G |
Sncb |
synuclein, beta |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of SNCB protein |
CTD |
PMID:23178681 |
|
NCBI chr17:10,384,472...10,392,776
Ensembl chr17:10,384,511...10,392,843
|
|
G |
Sod1 |
superoxide dismutase 1 |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of SOD1 protein |
CTD |
PMID:23178681 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sod3 |
superoxide dismutase 3 |
affects binding multiple interactions |
ISO |
SOD3 protein binds to Hyaluronic Acid SOD3 protein inhibits the reaction [[Copper co-treated with Hydrogen Peroxide] results in increased degradation of Hyaluronic Acid] |
CTD |
PMID:18165226 |
|
NCBI chr14:60,958,583...60,971,143
Ensembl chr14:60,958,592...60,964,324
|
|
G |
Sord |
sorbitol dehydrogenase |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of SORD protein] |
CTD |
PMID:23178681 |
|
NCBI chr 3:114,176,127...114,207,368
Ensembl chr 3:114,176,309...114,207,366
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
multiple interactions |
ISO |
[Hyaluronic Acid co-treated with resveratrol] results in increased expression of SOX9 mRNA |
CTD |
PMID:23595953 |
|
NCBI chr10:101,288,528...101,294,030
Ensembl chr10:101,288,489...101,293,379
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of SRC protein] |
CTD |
PMID:23178681 |
|
NCBI chr 3:153,547,807...153,595,643
Ensembl chr 3:153,580,861...153,595,642
|
|
G |
Stam2 |
signal transducing adaptor molecule 2 |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of STAM2 protein |
CTD |
PMID:23178681 |
|
NCBI chr 3:38,230,676...38,277,433
Ensembl chr 3:38,230,618...38,277,440
|
|
G |
Stip1 |
stress-induced phosphoprotein 1 |
multiple interactions decreases expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of STIP1 protein] Hyaluronic Acid analog results in decreased expression of STIP1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 1:222,274,133...222,293,139
Ensembl chr 1:222,274,133...222,293,148
|
|
G |
Tcp1 |
t-complex 1 |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of TCP1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 1:48,025,664...48,033,343
Ensembl chr 1:48,025,663...48,033,396
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[CD44 protein affects the abundance of Hyaluronic Acid] affects the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:31285260 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
multiple interactions increases abundance |
ISO |
MAP3K3 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid]; MAPK1 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid]; MAPK3 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid]; MAPK7 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid] |
CTD |
PMID:20633555 |
|
NCBI chr13:105,039,639...105,142,010
Ensembl chr13:105,039,853...105,141,030
|
|
G |
Tlr2 |
toll-like receptor 2 |
increases expression multiple interactions |
ISO |
Hyaluronic Acid metabolite results in increased expression of TLR2 mRNA; Hyaluronic Acid metabolite results in increased expression of TLR2 protein Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [Hyaluronic Acid metabolite results in increased expression of TLR2 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [Hyaluronic Acid metabolite results in increased expression of TLR2 protein] |
CTD |
PMID:23692848 |
|
NCBI chr 2:182,840,171...182,846,061
Ensembl chr 2:182,840,727...182,846,061
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions increases expression increases abundance |
ISO |
Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [Hyaluronic Acid metabolite results in increased expression of TLR4 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [Hyaluronic Acid metabolite results in increased expression of TLR4 protein] Hyaluronic Acid metabolite results in increased expression of TLR4 mRNA; Hyaluronic Acid metabolite results in increased expression of TLR4 protein TLR4 protein results in increased abundance of Hyaluronic Acid [Lipopolysaccharides results in decreased activity of TLR4 protein] inhibits the reaction [[Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of IL1B protein] |
CTD |
PMID:23692848 PMID:25053413 PMID:31226360 |
|
NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases abundance increases expression |
EXP ISO |
[Chondroitin Sulfates co-treated with Hyaluronic Acid] inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein] [acetic anhydride results in increased acetylation of Hyaluronic Acid metabolite] which results in increased secretion of TNF protein; [Butyrates results in increased acylation of Hyaluronic Acid metabolite] inhibits the reaction [[Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of TNF protein]; [Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of TNF protein TNF mRNA results in increased abundance of Hyaluronic Acid Hyaluronic Acid metabolite results in increased expression of TNF mRNA; Hyaluronic Acid metabolite results in increased expression of TNF protein |
CTD |
PMID:14697411 PMID:23692848 PMID:25053413 PMID:25106431 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
affects binding multiple interactions |
ISO |
TNFAIP6 protein modified form binds to Hyaluronic Acid TNFAIP6 protein promotes the reaction [ITIH1 protein binds to Hyaluronic Acid] |
CTD |
PMID:12401803 PMID:25561734 |
|
NCBI chr 3:37,545,238...37,564,704
Ensembl chr 3:37,545,238...37,564,699
|
|
G |
Tpm2 |
tropomyosin 2 |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of TPM2 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 5:59,016,616...59,025,971
Ensembl chr 5:59,016,622...59,025,631
|
|
G |
Tpm3 |
tropomyosin 3 |
multiple interactions decreases expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of TPM3 protein] Hyaluronic Acid analog results in decreased expression of TPM3 protein |
CTD |
PMID:23178681 |
|
NCBI chr 2:189,423,534...189,451,340
Ensembl chr 2:189,423,559...189,451,029
|
|
G |
Tpt1 |
tumor protein, translationally-controlled 1 |
decreases expression |
EXP |
Hyaluronic Acid analog results in decreased expression of TPT1 protein |
CTD |
PMID:23178681 |
|
NCBI chr15:57,891,680...57,894,504
Ensembl chr15:57,891,680...57,894,504
|
|
G |
Tubb5 |
tubulin, beta 5 class I |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of TUBB5 protein] |
CTD |
PMID:23178681 |
|
NCBI chr20:3,422,448...3,426,420
Ensembl chr20:3,422,461...3,426,371
|
|
G |
Vcp |
valosin-containing protein |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of VCP protein] |
CTD |
PMID:23178681 |
|
NCBI chr 5:58,426,548...58,445,953
Ensembl chr 5:58,426,549...58,445,953
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
Hyaluronic Acid promotes the reaction [Dipyridamole results in increased secretion of VEGFA protein] |
CTD |
PMID:20067761 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Vim |
vimentin |
increases expression multiple interactions affects expression |
ISO EXP |
Hyaluronic Acid analog results in increased expression of VIM protein Hyaluronic Acid analog affects the reaction [Hydrogen Peroxide affects the expression of VIM protein] Hyaluronic Acid analog affects the expression of VIM protein |
CTD |
PMID:20159036 PMID:23178681 |
|
NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
|
|
G |
Vps33a |
VPS33A core subunit of CORVET and HOPS complexes |
multiple interactions increases expression |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of VPS33A protein] Hyaluronic Acid analog results in increased expression of VPS33A protein |
CTD |
PMID:23178681 |
|
NCBI chr12:38,459,816...38,482,903
Ensembl chr12:38,459,832...38,484,512
|
|
G |
Wdr1 |
WD repeat domain 1 |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of WDR1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr14:76,990,014...77,023,739
Ensembl chr14:76,989,919...77,023,726
|
|
G |
Yars1 |
tyrosyl-tRNA synthetase 1 |
multiple interactions |
EXP |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of YARS1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 5:147,375,350...147,403,578
Ensembl chr 5:147,375,350...147,403,571
|
|
|
G |
B3gnt2 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 |
increases chemical synthesis |
ISO |
B3GNT2 protein results in increased chemical synthesis of Keratan Sulfate |
CTD |
PMID:12218059 |
|
NCBI chr14:107,592,336...107,617,189
Ensembl chr14:107,592,336...107,617,161
|
|
G |
B4galt1 |
beta-1,4-galactosyltransferase 1 |
increases chemical synthesis |
ISO |
B4GALT1 protein results in increased chemical synthesis of Keratan Sulfate |
CTD |
PMID:12218059 |
|
NCBI chr 5:57,121,768...57,168,610
Ensembl chr 5:57,121,769...57,168,610
|
|
G |
Chst5 |
carbohydrate sulfotransferase 5 |
multiple interactions |
ISO |
CHST6 protein results in increased sulfation of and results in increased chemical synthesis of Keratan Sulfate |
CTD |
PMID:12218059 |
|
NCBI chr19:44,115,065...44,136,092
Ensembl chr19:44,115,120...44,135,387
|
|
G |
Gns |
glucosamine (N-acetyl)-6-sulfatase |
affects degradation |
ISO |
GNS affects the degradation of Keratan Sulfate |
CTD |
PMID:3391615 |
|
NCBI chr 7:63,467,027...63,501,054
Ensembl chr 7:63,467,216...63,499,353
|
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
ALB protein inhibits the reaction [zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]] |
CTD |
PMID:19376148 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Aqp1 |
aquaporin 1 |
decreases expression multiple interactions |
ISO |
Peptidoglycan results in decreased expression of AQP1 mRNA; Peptidoglycan results in decreased expression of AQP1 protein SB 203580 inhibits the reaction [Peptidoglycan results in decreased expression of AQP1 protein] |
CTD |
PMID:21647617 |
|
NCBI chr 4:85,551,503...85,563,683
Ensembl chr 4:85,551,502...85,569,360
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
increases expression |
ISO |
Peptidoglycan results in increased expression of BCL2A1 mRNA |
CTD |
PMID:15860229 |
|
NCBI chr 8:96,551,424...96,559,527
Ensembl chr 8:96,551,245...96,559,483
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases secretion |
ISO |
Peptidoglycan results in increased secretion of CCL2 protein |
CTD |
PMID:15593098 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
increases expression |
ISO |
Peptidoglycan results in increased expression of CCL20 mRNA; Peptidoglycan results in increased expression of CCL20 protein |
CTD |
PMID:15191912 PMID:15860229 |
|
NCBI chr 9:88,918,359...88,921,017
Ensembl chr 9:88,918,433...88,921,001
|
|
G |
Clec7a |
C-type lectin domain containing 7A |
multiple interactions |
ISO |
CLEC7A protein promotes the reaction [Peptidoglycan results in increased metabolism of Leukotriene C4] |
CTD |
PMID:17030235 |
|
NCBI chr 4:163,216,152...163,227,367
Ensembl chr 4:163,216,163...163,227,334
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions increases expression |
ISO |
CSF2 protein promotes the reaction [Peptidoglycan results in increased secretion of CXCL8 protein] Peptidoglycan results in increased expression of CSF2 mRNA; Peptidoglycan results in increased expression of CSF2 protein |
CTD |
PMID:12176910 PMID:12574323 PMID:15191912 |
|
NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases secretion |
ISO |
Peptidoglycan results in increased secretion of CXCL2 protein |
CTD |
PMID:15593098 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Defb4 |
defensin beta 4 |
increases expression |
ISO |
Peptidoglycan results in increased expression of DEFB4 mRNA; Peptidoglycan results in increased expression of DEFB4 protein |
CTD |
PMID:15893496 |
|
NCBI chr16:75,634,598...75,637,789
Ensembl chr16:75,634,598...75,637,789
|
|
G |
Ehd1 |
EH-domain containing 1 |
increases expression |
ISO |
Peptidoglycan results in increased expression of EHD1 mRNA |
CTD |
PMID:15860229 |
|
NCBI chr 1:221,644,867...221,667,242
Ensembl chr 1:221,644,867...221,667,239
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
increases expression |
ISO |
Peptidoglycan results in increased expression of GADD45B mRNA |
CTD |
PMID:15860229 |
|
NCBI chr 7:11,646,283...11,648,338
Ensembl chr 7:11,646,269...11,648,322
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Peptidoglycan] results in increased expression of GPX1 protein; [Peptidoglycan co-treated with Lipopolysaccharides] promotes the reaction [Auranofin results in increased expression of GPX1 protein]; [Peptidoglycan co-treated with Lipopolysaccharides] promotes the reaction [Thiomalates results in increased expression of GPX1 protein]; Auranofin promotes the reaction [[Lipopolysaccharides co-treated with Peptidoglycan] results in increased expression of GPX1 protein]; Thiomalates promotes the reaction [[Lipopolysaccharides co-treated with Peptidoglycan] results in increased expression of GPX1 protein] |
CTD |
PMID:21355852 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
Peptidoglycan results in increased expression of ICAM1 mRNA |
CTD |
PMID:15860229 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Il10 |
interleukin 10 |
increases expression multiple interactions increases secretion |
ISO |
Peptidoglycan results in increased expression of IL10 protein Peptidoglycan results in increased expression of IL10 mRNA MYD88 gene mutant form inhibits the reaction [Peptidoglycan results in increased expression of IL10 protein]; Peptidoglycan results in increased expression of and results in increased secretion of IL10 protein Sirolimus inhibits the reaction [Peptidoglycan results in increased expression of IL10 protein] Peptidoglycan results in increased secretion of IL10 protein |
CTD |
PMID:11169223 PMID:16224278 PMID:17238832 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il12b |
interleukin 12B |
increases expression |
ISO |
Peptidoglycan results in increased expression of IL12B mRNA |
CTD |
PMID:15860229 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Peptidoglycan results in increased expression of IL1A mRNA |
CTD |
PMID:15860229 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
Peptidoglycan results in increased expression of IL1B mRNA; Peptidoglycan results in increased expression of IL1B protein |
CTD |
PMID:12574323 PMID:15860229 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il23a |
interleukin 23 subunit alpha |
increases expression |
ISO |
Peptidoglycan results in increased expression of IL23A mRNA |
CTD |
PMID:15860229 |
|
NCBI chr 7:2,710,609...2,712,723
Ensembl chr 7:2,710,609...2,712,723
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO |
[Lipopolysaccharides co-treated with Peptidoglycan] results in increased secretion of IL6 protein Peptidoglycan results in increased expression of IL6 mRNA |
CTD |
PMID:12185005 PMID:15860229 PMID:21355852 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Peptidoglycan results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Peptidoglycan results in increased phosphorylation of MAPK1 protein]; zinc protoporphyrin promotes the reaction [Peptidoglycan results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:19376148 PMID:21647617 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO |
Peptidoglycan results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Peptidoglycan results in increased phosphorylation of MAPK3 protein]; zinc protoporphyrin promotes the reaction [Peptidoglycan results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:19376148 PMID:21647617 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation |
ISO |
Peptidoglycan results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:21647617 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
increases expression |
ISO |
Peptidoglycan results in increased expression of MMP1 mRNA |
CTD |
PMID:15860229 |
|
NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
increases expression multiple interactions |
ISO |
Peptidoglycan results in increased expression of MYD88 protein MYD88 gene mutant form inhibits the reaction [Peptidoglycan results in increased expression of IL10 protein] |
CTD |
PMID:15593098 PMID:17238832 |
|
NCBI chr 8:128,022,512...128,027,462
Ensembl chr 8:128,022,473...128,026,841
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
ISO |
ALB protein inhibits the reaction [zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]]; lactacystin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]]; pyrazolanthrone inhibits the reaction [zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]]; zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein] |
CTD |
PMID:19376148 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Pla2g5 |
phospholipase A2, group V |
multiple interactions |
ISO |
PLA2G5 protein promotes the reaction [Peptidoglycan results in increased metabolism of Eicosanoids] |
CTD |
PMID:17369491 |
|
NCBI chr 5:157,247,601...157,268,968
Ensembl chr 5:157,247,781...157,268,903
|
|
G |
Prdx3 |
peroxiredoxin 3 |
multiple interactions |
ISO |
[[Lipopolysaccharides co-treated with Peptidoglycan] co-treated with Thiomalates] results in increased expression of PRDX3 protein; [Lipopolysaccharides co-treated with Peptidoglycan] results in increased expression of PRDX3 protein; Auranofin promotes the reaction [[Lipopolysaccharides co-treated with Peptidoglycan] results in increased expression of PRDX3 protein] |
CTD |
PMID:21355852 |
|
NCBI chr 1:282,238,774...282,251,193
Ensembl chr 1:282,238,773...282,251,257
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
Peptidoglycan results in increased expression of PTGS2 mRNA |
CTD |
PMID:15860229 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
affects localization |
ISO |
Peptidoglycan affects the localization of RELA protein |
CTD |
PMID:15893496 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Sesn2 |
sestrin 2 |
increases expression |
ISO |
Peptidoglycan results in increased expression of SESN2 mRNA |
CTD |
PMID:25637945 |
|
NCBI chr 5:150,684,891...150,703,846
Ensembl chr 5:150,684,133...150,704,117
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression |
ISO |
Peptidoglycan results in increased expression of SOD2 mRNA |
CTD |
PMID:15860229 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Syk |
spleen associated tyrosine kinase |
multiple interactions |
ISO |
SYK protein promotes the reaction [Peptidoglycan results in increased metabolism of Leukotriene C4] |
CTD |
PMID:17030235 |
|
NCBI chr17:12,614,311...12,669,568
Ensembl chr17:12,614,311...12,669,573
|
|
G |
Tlr2 |
toll-like receptor 2 |
multiple interactions affects response to substance increases expression |
ISO |
Peptidoglycan binds to and results in increased activity of TLR2 protein Peptidoglycan binds to and results in increased activity of TLR2 protein; TLR2 protein promotes the reaction [Peptidoglycan results in increased metabolism of Eicosanoids] TLR2 protein affects the susceptibility to Peptidoglycan Peptidoglycan results in increased expression of TLR2 mRNA; Peptidoglycan results in increased expression of TLR2 protein |
CTD |
PMID:12734376 PMID:15593098 PMID:17369491 |
|
NCBI chr 2:182,840,171...182,846,061
Ensembl chr 2:182,840,727...182,846,061
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO |
Peptidoglycan results in increased expression of TNF mRNA; Peptidoglycan results in increased expression of TNF protein Cannabidiol analog inhibits the reaction [Peptidoglycan results in increased expression of TNF protein] |
CTD |
PMID:11169223 PMID:15860229 PMID:15893496 PMID:30796934 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
increases expression |
ISO |
Peptidoglycan results in increased expression of TNFAIP6 mRNA |
CTD |
PMID:15860229 |
|
NCBI chr 3:37,545,238...37,564,704
Ensembl chr 3:37,545,238...37,564,699
|
|
G |
Txn2 |
thioredoxin 2 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Peptidoglycan] results in increased expression of TXN2 protein; Thiomalates promotes the reaction [[Lipopolysaccharides co-treated with Peptidoglycan] results in increased expression of TXN2 protein] |
CTD |
PMID:21355852 |
|
NCBI chr 7:119,144,350...119,158,173
Ensembl chr 7:119,144,351...119,158,201
|
|
|
G |
Chst5 |
carbohydrate sulfotransferase 5 |
increases sulfation |
ISO |
CHST6 protein results in increased sulfation of poly-N-acetyllactosamine |
CTD |
PMID:12218059 |
|
NCBI chr19:44,115,065...44,136,092
Ensembl chr19:44,115,120...44,135,387
|
|